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ABSTRACT 
 
DENNIS R. SPARTA: Rodent Models of Human Alcoholism: Implications for a  
 
Role of Neuropeptide Y and Corticotropin Releasing Factor 
 
(Under the direction of Todd E. Thiele) 
 
 Rodent models of alcoholism have been integral in discovering candidate 
genes and neurochemicals involved in this disease.  Two promising candidates 
include neuropeptide Y (NPY) and corticotropin releasing factor (CRF).   It has been 
hypothesized that NPY and CRF exert a reciprocal regulation of ethanol self-
administration through allosteric interactions within the extended amygdala.  
Therefore, the goal of the present report was to determine if NPY and CRF modulate 
ethanol relapse- and binge-like drinking behaviors through the use of recently 
developed rodent models.  Experiment 1 utilized the NPY -/- mouse to determine if 
NPY modulates withdrawal-induced anxiety, a component of ethanol relapse.  
Compared to the NPY +/+ mice, NPY -/- mice exhibited increased withdrawal-
induced anxiety as measured by the elevated plus maze (EPM) test.  Although, we 
did not examine CRF, previous research has revealed that a hyperactive CRF 
system contributes to withdrawal-induced anxiety.  Experiment 2 expanded on 
previous findings by examining the role of NPY and CRF on excessive ethanol 
relapse-like consumption, as measured by the alcohol deprivation effect (ADE).  We 
 iii
found that female NPY -/- mice exhibited increased post-deprivation ethanol drinking 
(i.e., the ADE) that endured for several deprivation cycles.  Interestingly, the male 
NPY -/- mice did not exhibit the ADE during any deprivation cycle.  Additionally, we 
found that acute administration of CP-154,526, a highly selective CRF1 receptor 
antagonist, reduced the expression of the ADE in mice. Experiment 3 examined the 
role of CRF on excessive or binge-like drinking as modeled by drinking in the dark 
(DID) procedures.  We found that administration of CP-154,526 reduced excessive, 
but not moderate, ethanol drinking suggesting a possible role for CRF in binge 
drinking.  Taken together, these experiments provide evidence for a role of both 
NPY and CRF in the modulation of multiple behaviors and neurobiological 
responses that may underlie alcohol abuse disorders and alcoholism.  Ultimately, 
pharmacological compounds that target these systems may be of potential 
therapeutic value for the treatment of alcoholism. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Alcoholism is a complex disease characterized by progressive and persistent 
patterns of drinking.  Defining characteristics of the disease include: preoccupation 
with drinking, development of tolerance and dependence, and loss of control over 
drinking (DSM-IV, 1994).  According to a National Institute on Alcohol Abuse and 
Alcoholism (NIAAA) database, approximately 15.1 million people are considered 
alcoholics in the United States. One factor that has made it difficult to treat 
alcoholism is that it is often found co-morbid with other psychiatric disorders 
including depression and anxiety (Schuckit and Hesselbrock, 1994; Grant et al., 
2004). An additional complication is that evidence suggests that the underpinnings 
of alcoholism are many; thus there are multiple alcoholic types that require different 
treatment strategies. One simple approach to describing alcoholics has been to 
subdivide them into two groups.  Type 1 alcoholics develop the disease later in life 
and have a tendency to exhibit anxiety-related disorders.  Type II alcoholics are 
more prevalent and are characterized by an earlier age of onset and heightened 
impulsivity (Cloninger, 1987).  Given the different characteristics associated with 
each alcoholic type, the effective treatment of excessive ethanol use by each group 
will likely require different approaches. 
Current Pharmacological Treatments of Alcoholism 
Currently, there are three FDA approved pharmacological treatments for 
alcoholism: disulfiram, naltrexone, and acamprosate.  Disulfiram was the first 
approved drug. This drug prevents the normal breakdown of ethanol by the enzyme 
aldehyde dehydrogenase, which results in an excessive accumulation of 
acetaldehyde (Johansson, 1992).  Increases in levels of acetaldehyde lead to 
aversive symptoms such as nausea, tachycardia, headache, shortness of breath 
and flushing (Heilig and Egli, 2006).  It has been hypothesized that the alcoholic will 
avoid consuming ethanol after administration of disulfiram in order to avoid the 
unpleasant side effects.  However, compliance is a major issue in the efficacy of this 
drug as only 19% of patients report adherence to the drug regimen (Fuller et al., 
1986). Furthermore, potential life-threatening toxic effects associated with excessive 
ethanol use in the presence of disulfiram have limited the use of this drug in the 
treatment of alcoholism (Heilig and Egli, 2006). The second FDA approved 
pharmacotherapy involves the use of opioid receptor antagonists, such as the drug 
naltrexone.  Naltrexone is a nonselective opioid receptor antagonist, and has been 
shown to attenuate the reinforcing properties of ethanol (Volpicelli et al., 1997).  For 
example, naltrexone blocked the “high” associated with ethanol consumption in a 
high risk population (King et al., 1997).  Acamprosate is a third drug that has been 
approved for the treatment of alcoholism.  Repeated cycles of ethanol withdrawal 
and relapse lead to an increase in extracellular glutamate (Spanagel and 
Bienkowski, 2002; Tsai and Coyle, 1998).  Acamprosate appears to reduce this 
increased glutamatergic signaling by blocking both the NMDA and metabotropic 
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glutamate receptor (Spanagel and Zieglgansberger, 1997; Harris et al., 2002).  
Currently, naltrexone and acamprosate are the most commonly prescribed drugs for 
the treatment of alcoholism. Interestingly, naltrexone appears to be more effective in 
treating early onset alcoholism (Type II) while acamprosate is more effective in 
treating the latter onset Type I alcoholism (Heilig and Egli, 2006 for review; O’Malley 
et al., 1992; Rimondini et al., 2002).  Unfortunately, several clinical studies have 
revealed the limited efficacy of both naltrexone and acamprosate in ethanol abuse 
treatment, which has spurred research to find new pharmacological targets (Anton et 
al., 1999; Chick et al., 2000; Namkoong et al., 2003; Volpicelli et al., 1997). Because 
alcoholism is a complex disease characterized by behaviors and neurobiological 
responses associated with 1) uncontrolled excessive ethanol intake, 2) withdrawal 
from ethanol, and 3) relapse, it is essential to recognize these different phases of the 
disease when developing pharmacological targets for treating ethanol abuse 
disorders. Clearly, procedures are required that can model these different 
components of alcoholism in animals.  Over that last 10 years, several new animal 
models of alcoholism and alcohol abuse disorders have been developed.   
 
Animal Models of Human Alcoholism 
Animal models are useful tools for examining potential pharmacological 
targets for the treatment of alcoholism.  Although any one model cannot replicate 
every facet of the human condition, recent models have been validated to mimic 
certain behavioral and/or neurobiological features of this disease.  Cicero (1979) 
proposed the first set of criteria for rodent models of alcoholism which include the 
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following: rodents should voluntarily self-administer ethanol, animals should attain 
pharmacologically relevant blood ethanol concentrations (BEC), ethanol should be 
consumed for its post-ingestive effects, ethanol should be positively reinforcing, and 
chronic ethanol consumption should lead to tolerance and dependence. More 
recently, the criteria that animal models should also display characteristics 
associated with relapse has been added to the list (McBride and Li, 1998). 
 
Models of Voluntary Ethanol Consumption 
Voluntary ethanol consumption models have been the most commonly used 
approach to study the genetics and pharmacology of alcoholism.  With this 
approach, animals (typically rats or mice) are given a free choice between a water 
and ethanol solution in two different bottles.  Food is available ad libitum so that the 
animals are not required to drink ethanol to obtain calories.   Based on their 
consumption of the fluids, a preference ratio is typically calculated by dividing the 
amount of ethanol consumed by total fluid intake (ethanol plus water).  These 
studies have been integral in the development of selectively bred strains including 
the Indiana Alcohol-Preferring (P) and Alcohol-Non-Preferring (NP) rat lines 
(McBride and Li, 1998).  The P rat, which has been bred for over 55 generations, 
voluntarily consumes more than 5 g/kg of ethanol per day and achieves average 
BECs of approximately 200mg/dL or 0.2% during 24-hour free choice ethanol self-
administration (Li et al., 1993; Murphy et al., 1986; Murphy et al., 2002; Rodd-
Henricks et al., 2000; Waller et al., 1982).  Other rat lines, which have been created 
using selective breeding strategies include: the Alko Alcohol (AA) and Alko 
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Nonalcohol (ANA) lines, the High Alcohol Drinking (HAD) and Low Alcohol Drinking 
(LAD) lines, and the Sardinian Preferring (sP) and Sardinian Non-preferring (sNP) 
lines (Colombo, 1997; Eriksson, 1968; Li et al., 1993). However, many rodent strains 
do not achieve relevant BECs through two bottle choice alone and do not 
demonstrate uncontrolled ethanol drinking (Belknap et al., 1993).   For example, 
C57BL/6 mice, a strain noted for their high ethanol preference, will prefer a solution 
sweetened with sugar over ethanol. Additionally, they will avoid drinking ethanol 
which is adulterated with a bitter quinine taste. Both of these characteristics suggest 
that voluntary ethanol drinking is not “uncontrolled” by C57BL/6 mice (Spanagel, 
2000). Observations such as these, and the fact the voluntary consumption does not 
model features such as withdrawal symptoms and relapse, have led to the 
development of alternative procedures to model alcoholism.  
 
Animal Models of Excessive Relapse-Like Drinking: The Alcohol Deprivation Effect 
Human alcoholics are often characterized by cycles of abstinence and 
ethanol use (Holly and Wittchen, 1998).  Immediately following a period of 
abstinence, individuals will often consume copious amounts of ethanol for a short 
period of time in the beginning of a relapse period, which is often considered to be a 
hallmark feature of relapse (Burish et al., 1981; Chiauzzi et al., 1991; Mello and 
Mendelson, 1972).  This phenomenon has been labeled the alcohol deprivation 
effect (ADE).  In animals, the ADE is characterized by a transient (1-2 days) 
increase of ethanol consumption upon the return of ethanol following a period of 
forced abstinence.  The increased ethanol drinking that is associated with the ADE 
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appears to be uncontrolled because the addition of quinine to the ethanol solution 
does not attenuate or prevent increased ethanol drinking as it does with non-ADE 
ethanol drinking (Spanagel, 2000). The ADE has been observed in many different 
species including rats, mice, and monkeys (Kornet et al., 1990; McKinzie et al., 
1998; Rodd-Hendricks et al., 2000; Salimov et al., 1993; Sinclair, 1971; Sinclair and 
Senter, 1967).  This model has been studied extensively in the P rat.  P rats that had 
continuous 1-month access to ethanol using two-bottle consumption procedures 
exhibited an ADE after a 12-hour or 7-day deprivation period (Sinclair and Li, 1989). 
Additionally, P rats exhibited an ADE using operant self-administration procedures 
(McKinzie et al., 1998), and repeated cycles of ethanol deprivations increased the 
magnitude and duration of the ADE in P rats (Rodd et al., 2003).  Importantly, drugs 
such as acamprosate and naltrexone have been shown to reduce the ADE in 
rodents suggesting that opioid and glutamate receptor signaling modulate ADE 
drinking (Spanagel et al., 1996; McBride et al., 2002).  These latter observations 
support the idea that these drugs may be useful for treating or preventing 
uncontrolled relapse-like drinking in humans. 
 
Animal Models of Binge-Like Drinking: The Drinking in the Dark Procedure 
Binge or excessive drinking is often a first step to the development of 
alcoholism.  Recently, procedures labeled “drinking in the dark” (DID) were 
developed in which C57BL/6J mice will rapidly consume enough ethanol over a 
short period of time such that they can achieve pharmacologically significant BECs. 
With this procedure, C57BL/6J mice are individually housed with access to water 
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and food. Then, the water bottle is replaced with a bottle containing 20% ethanol for 
2-4-hours, beginning 3-hours into the dark cycle (Rhodes et al., 2005; 2007).  During 
this limited ethanol access, mice drink to the point of behavioral intoxication and 
achieve BECs of approximately 100 mg/dL or 0.1% (Rhodes et al., 2007).  This BEC 
is approximately equal to what would be achieved by 4-6 drinks over a 2-hour period 
in an average sized male and thus considered an animal model of human binge-
drinking (Rhodes et al., 2005). The DID model has been suggested to have 
predictive validity for testing potential pharmacological targets as naltrexone, a drug 
used to treat ethanol abuse disorders, prevents binge-like drinking associated with 
DID procedures (Kamdar et al., 2007). 
 
Animal Models of Relapse: Reinstatement of Ethanol-Seeking Behavior 
In human alcoholics, stress and cues associated with ethanol such as 
ethanol’s smell, pictures of ethanol, ethanol-associated words, contextual cues 
associated with drinking (e.g., bars, friends, etc.) have been demonstrated to 
increase the urge to drink (Cox et al.,1999; Ludwig, 1986; Monti et al., 1999; Tapert 
et al., 2004).  These “cravings” elicited by ethanol-associated cues and/or stress are 
thought to increase the risk of relapse.  Reinstatement procedures have been used 
to model relapse in rodents.  The basic procedure involves first training the rodent to 
press a lever (or some other operant behavior) in order to gain access to an ethanol 
reinforcer. As a control for specificity of treatment to ethanol-seeking behavior, a 
second lever is typically available that is either inactive or reinforced with water. 
Once ethanol-reinforced behavior is established and stable, rodents experience an 
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extinction procedure in which lever pressing is no longer reinforced with ethanol. 
Following extinction, various stimuli are presented to the animal to determine if they 
can reinstate lever pressing behavior despite the continued absence of ethanol 
reinforcement.  Three types of stimuli have been shown to induce reinstatement of 
ethanol-seeking behavior: exposure to ethanol via intraperitoneal (i.p.) injection  (i.e., 
priming injections), exposure to a stressor such as intermittent foot shock, and 
conditioned stimuli that were previously paired with the ethanol reinforcer.   
Exposure to ethanol, such as the consumption of a single alcoholic beverage, 
is enough to trigger relapse in the human alcoholic (Bigelow et al., 1977; de Wit, 
1996; Ludwig and Wilker, 1974; Ludwig et al., 1974).  Rats that have a limited 
access to an ethanol solution or receive a priming dose of ethanol will also reinstate 
drug-seeking behavior (Chiamulera et al., 1995; Le et al., 1998; 1999).  Clinical 
studies show that stress will induce craving in the abstinent alcoholic (Breslau et al., 
2003).  It is hypothesized that the abstinent alcoholic relapses in order to attenuate 
the heightened anxiety associated with stressful life events (Brady and Sonne, 2005; 
Kushner et al., 1994; Sinha, 2001).  Stressors such as foot shock will elicit 
reinstatement of ethanol-seeking behavior in rodents (Le et al., 1998; Martin-Fardon 
et al., 2000; Shaham et al., 2000).  Conditioned environmental cues also contribute 
to relapse in humans (Ludwig et al., 1986; O’Brien et al., 1998).  Contexts, such as 
bars, and images of ethanol influence craving and increase drinking levels in 
humans (Collins and Brandon, 2002; Staiger and White, 1988).  These effects are 
also demonstrated in the animal literature.   Ethanol associated olfactory cues, 
auditory and visual stimuli have been able to reinstate ethanol-seeking behavior in 
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rodents (Backstrom et al., 2004; Ciccocioppo et al., 2001; Ciccocioppo et al., 2004; 
Katner et al., 1999; Nie and Janak, 2003).  The opioid and corticotropin releasing 
factor (CRF) systems have been implicated in the modulation of reinstatement of 
ethanol-seeking behaviors.  Administration of naltrexone protects against priming 
injection- and conditioned cue-induced reinstatement of ethanol-seeking behavior. 
(Bienkowski et al., 1999, Ciccocioppo et al., 2002, 2003; Katner et al., 1999; Le et 
al., 1999).  Additionally, administration of CRF antagonists prevents reinstatement 
caused by foot shock in rats (Liu and Weiss, 2002).  These observations 
demonstrate the potential usefulness of this model for identifying potential 
pharmacological targets for treating or preventing relapse in humans. 
 
Animal Models of Ethanol Dependence 
One frequent criticism of animal models of alcoholism is that animals do not 
consume enough ethanol over a sufficient period of time to achieve physiological 
dependence.  To address this concern, several models of ethanol dependence have 
been developed.  Procedures associated with these models involve forced exposure 
to ethanol in such a way that rodents achieve a high and sustained blood ethanol 
level, typically 150 to 200 mg/dL (0.15 to 0.2 %). In one typical procedure, animals 
are given access to a nutritionally complete liquid diet containing ethanol. Animals 
also have access to a water bottle but do not have access to chow, thus they are 
forced to drink the ethanol diet to maintain their nutritional balance. One drawback 
with this method that has been noted is that since ethanol intake is under the control 
of the rodent, BECs can fluctuate within and between days due to factors such as 
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sleep cycles (Rogers et al., 1979).  A second procedure utilizes ethanol 
vaporization/volatilization as a means of exposing rodents to ethanol via inhalation. 
Typically, rodents are housed in chambers in which ethanol vapor and air are mixed 
in controlled amounts.  The benefit of this method is that BECs can be vigorously 
maintained throughout the experiment.  Recent research using these procedures 
have revealed that animals chronically exposed to high BECs show increased 
voluntary ethanol consumption relative to non-ethanol exposed rodents, suggesting 
the development of ethanol dependence (Becker and Lopez, 2004; Finn et al., 2007; 
Lopez and Becker, 2005; O’Dell et al., 2004; Rimondini et al., 2003; Roberts et al., 
1996; Roberts et al., 2000).  Interestingly, administration of corticotropin releasing 
factor (CRF) receptor antagonists reduce ethanol intake in dependent rodents but 
have no effect on ethanol drinking in non-dependent rodents (Finn et al., 2007; 
Gehlert et al., 2007; Valdez et al., 2002). Similarly, central infusion of neuropeptide Y 
(NPY) reduced ethanol drinking by dependent Wistar rats but did not influence 
ethanol intake in non-dependent Wistars (Thorsell et al., 2005a,b). Increased 
anxiety-like behavior is observed following withdrawal from ethanol diet or vapor 
exposure, and increased anxiety-like behavior is blocked by CRF receptor 
antagonists (Baldwin et al., 1991; Overstreet et al., 2004; Rassnick et al., 1993).  
Thus, procedures that can achieve high and prolonged BECs have begun to reveal 
neurochemical pathways that modulate neurobiological responses associated with 
ethanol dependence. 
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Allostasis Theory of Alcoholism 
The animal models described above have been developed to study the 
neurobiology underlying various features associated with alcoholism and ethanol 
abuse disorders. An interesting observation with some of these models, such as the 
ADE and ethanol dependence procedures, is that pharmacological compounds that 
can reduce ethanol intake in dependent, or ethanol deprived, rodents are ineffective 
in altering ethanol consumption in non-dependent animals. Thus, as noted above 
administration of CRF receptor antagonists or NPY agonists reduce increased 
ethanol intake in dependent animals but are without effects in non-dependent 
rodents. Because of their opposing actions on dependence-induced ethanol 
consumption, it has been suggested that CRF and NPY exert a reciprocal regulation 
of ethanol responsiveness through homeostatic interactions in the amygdala (Heilig 
et al., 1994). More recently, an allostasis model of regulation has been proposed 
(Koob, 2003; Koob & LeMoal, 2001). According to this model, chronic exposure to 
stressors, including drugs, promote changes to the processes that maintain the 
system’s “set point”. Uncontrolled ethanol drinking stemming from repeated 
abstinence and relapse evolves as a consequence of a weakened NPY system and 
a hyperactive CRF system. Koob suggests that the “extended amygdala NPY 
system is compromised during the development of dependence and, combined with 
an activated extended amygdala CRF system, provides a powerful contribution to 
the negative affective state that drives the negative reinforcement of acute 
withdrawal and protracted abstinence” (Koob, 2003). Viewed this way, repeated 
exposure and withdrawal from ethanol alters the delicate balance between the 
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amygdalar NPY and CRF systems. This imbalance results in a negative affective 
state that increases the likelihood of relapse and promotes uncontrolled ethanol 
drinking. Thus, changes to the NPY and CRF systems following chronic use and 
repeated withdrawal may contribute to ethanol dependence.  
Recent evidence has emerged consistent with predictions based on the 
allostasis model. Changes in both CRF and NPY levels are seen following chronic 
ethanol administration and withdrawal.  Thus, increased CRF immunoreactivity is 
observed in the amygdala following a 6-week ethanol deprivation period after 
chronic ethanol exposure (Zorilla et al., 2001).  Additionally, NPY expression is 
decreased during ethanol withdrawal in the central nucleus of the amygdala (Roy 
and Pandey, 2002; Pandey et al.; 2003b). Manipulations of CRF or NPY during 
ethanol withdrawal can alter anxiety-like behavior. Administration of a CRF 
antagonist reduces anxiety-like behavior stemming from the ethanol withdrawal 
(Overstreet et al., 2002; 2004).  Additionally, administration of a protein kinase A 
(PKA) activator normalizes NPY levels and blocks increased anxiety-like behavior in 
ethanol withdrawn rats (Pandey, 2003).  Therefore, it is hypothesized that a 
hyperactive CRF system and a weakened NPY system leads to a negative affective 
state which leads to ethanol relapse and dependence.  The hypothesized roles that 
the allostasis model attributes to CRF and NPY in the development of ethanol 
dependence, in combination with the converging evidence for a role of these 
neuropeptides in modulating neurobiological responses to ethanol as described 
above (also, see below), makes these neuropeptides attractive targets for continued 
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research in the development of compounds for treating alcoholism. The following is 
a brief overview of the neurobiological characteristics of NPY and CRF. 
 
Neuropeptide Y 
NPY is a 36 amino acid neuromodulator belonging to the PP-fold family of 
peptides and is widely expressed throughout the central nervous system (CNS) 
(Berglund et al., 2003; Colmer and Wahlestedt, 1993; Dumont et al., 1992; Gray and 
Morley, 1986).  There are currently 5 known receptor subtypes in the mouse, Y1, Y2, 
Y4, Y5, and Y6, all of which couple to Gi/o proteins, which inhibit the production of 
cyclic adenosine monophasphate (cAMP) (Palmiter et al., 1998).  However, only the 
Y1, Y2, and Y5 receptor subtypes are expressed centrally.  NPY has been shown to 
be involved in a diverse array of biological functions including the control of food 
intake, neuronal development, seizure activity, cardiovascular homeostasis, the 
integration of emotional behavior, thermogenesis, circadian rhythms, pain 
modulation, reproduction, and the neurobiological responses to ethanol (Biello et al., 
1997; Clark et al., 1984; Golombek et al., 1996; Gribkoff et al., 1998; Hansel et al., 
2001 a. b.; Harrington and Schak, 2000; Heilig et al., 1993; Heilig and Widerlove, 
1995; Kalra et al., 1998; Kasuya et al., 1998; Levine and Morley, 1984; Lopez-
Valpuesta et al., 1996; Pedrazzini et al., 1998; Shi et al., 1999; 2001; Woldbye et al., 
1996; 1997).  Recent evidence has emerged implicating NPY in the neurobiological 
responses to ethanol and drugs of abuse (Pandey et al., 2003a; Thiele et al., 2003).  
A genetic linkage analysis conducted in the F2 intercross progenies of selectively 
bred alcohol-preferring (P) and non-preferring (NP) rats revealed a chromosomal 
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region that includes the gene for the NPY precursor (Bice et al., 1998; Carr et al., 
1998).  Administration of ethanol and ethanol withdrawal alter central NPY 
expression in rodent models (Bison and Crews 2003; Clark et al., 1998, Ehlers et al., 
1998; Kinoshita et al., 2000; Roy and Pandey, 2002; Thiele et al., 2000).  I.c.v. 
infusion of NPY significantly decreases ethanol withdrawal responses in Wistar rats 
(Woldbye et al., 2002).  Data has also emerged examining the various NPY receptor 
subtypes involved in mediating NPY’s effects on ethanol.  Voluntary ethanol 
consumption and resistance to the intoxicating effects of ethanol are inversely 
related to NPY levels in knockout and transgenic mice (Thiele et al., 1998).  Other 
transgenic models have also demonstrated the same trend.  Mice lacking the NPY 
Y1 receptor exhibit increased ethanol consumption when compared to their wildtype 
controls (Thiele et al., 2002).  Additionally, mice lacking the NPY Y2 receptor, a 
presynaptic autoreceptor, exhibit decreased ethanol consumption relative to their 
wildtype controls (Thiele et al., 2004).  However, NPY Y5 -/- mice do not exhibit 
altered ethanol consumption (Thiele et al., 2000).  I.c.v. administration of NPY 
reduces ethanol consumption in P rats and high alcohol drinking (HAD) rats (Badia-
Elder et al., 2001; 2003).  Infusion of a selective NPY Y2 receptor antagonist, 
BIIE02446, reduced operant self-administration of ethanol by rats (Thorsell et al., 
2002).  Amygdalar infusion of a selective NPY Y1 receptor antagonist, BIBP 3226, 
increased operant ethanol self-administration in rats (Schroeder et al., 2003a).  
Additionally, injection of a selective NPY Y5 receptor antagonist, L-152,804 did not 
alter operant ethanol self-administration in rats (Schroeder et al., 2003b).  These 
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studies indicate that NPY modulates its effects on the neurobiological effects of 
ethanol via the Y1 and Y2 receptor subtypes but not the Y5 receptor subtype. 
 
Corticotropin Releasing Factor 
CRF is a 41 amino acid neuromodulator that is widely expressed throughout 
the central nervous system (Bloom et al., 1982; Merchenthaler et al., 1982).  There 
are currently two known CRF receptor subtypes in the mouse, CRF1 and CRF2, that 
couple to Gs proteins which increase the production of cAMP (Chalmers et al., 1996; 
Chen et al., 1993; Dautzenberg et al., 1997; Perrin et al., 1995)   Activation of the 
CRF1 receptor has been shown to increase anxiety-like behavior and stress 
responsiveness, whereas activation of the CRF2 receptor decreases both anxiety 
and stress and reduces appetite (Bale and Vale, 2004; Coste et al., 2006; Koob and 
Heinrichs, 1999; Koob and Thatcher-Britton, 1985; Reul and Holsboer, 2002; Timpl 
et al., 1998; Zobel et al., 2000).  CRF neurons located in the central amygdala have 
been shown to be involved in the anxiogenic effects of ethanol withdrawal (Heilig et 
al., 1994).  Increases in CRF immunoreactivity are seen in the amygdala following 
chronic administration of ethanol and during acute withdrawal (Richter and Weiss, 
1999; Olive et al., 2002; Zorilla et al., 2001).  Pharmacological manipulations of the 
CRF system have also been shown to alter ethanol consumption.  Stress-induced 
reinstatement of operant ethanol self-administration is reduced after administration 
of a CRF antagonist and increased by central infusion of CRF (Le et al., 2000; 
Stewart, 2000).  Central infusion of a CRF receptor antagonist, D-Phe-CRF(12-41), 
elevated ethanol self-administration after a period of ethanol deprivation in ethanol-
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dependent rats (Valdez et al., 2002).  It is believed that CRF exerts its effects on 
ethanol consumption via the CRF1 receptor.  Pharmacologically, antagonism of the 
CRF1 receptor can attenuate excessive ethanol intake in dependent, but not non-
dependent rodents (Finn et al., 2007; Gehlert et al. 2007; Valdez et al., 2002).  
Genetically, CRF1 receptor deficient mice self administer less ethanol than wild-type 
controls following a period of ethanol deprivation (Chu et al., 2007).  
 
Goals of the Dissertation 
The main goal of the present dissertation is to further characterize the roles of 
NPY and CRF in the modulation of neurobiological responses to ethanol. 
Specifically, the present studies have utilized some of the recently developed 
models outlined above to determine the potential roles of these neuropeptides in 
modulating specific features of alcoholism. Both pharmacological and genetic 
(mutant knockout mice) tools were used to address the hypotheses. First, Chapter 2 
further characterizes the role of NPY in modulating neurobiological responses 
associated with ethanol dependence and withdrawal. To this end, both NPY-/- and 
NPY+/+ mice were given continuous access to an ethanol-containing diet and then 
withdrawn from ethanol. An elevated plus maze procedure was then used to 
determine the role of NPY in modulating withdrawal-induced anxiety-like behavior in 
these mice. Chapter 3 assessed the roles of CRF (pharmacologically) and NPY 
(genetically) in the modulation of the ADE to determine the potential roles of these 
neuropeptides in modulating relapse-like behaviors. Finally, Chapter 4 combined 
pharmacological blockade of the CRF1 receptor with DID procedures to determine 
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the potential role of CRF1 receptor signaling in the modulation of excessive binge-
like ethanol drinking in C57BL/6J mice. These studies expand our current 
understanding of the roles that CRF and NPY signaling play in modulating the 
various behavioral and neurobiological features associated with alcoholism and 
alcohol abuse disorders, and suggest additional therapeutic avenues for treating this 
disease. 
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CHAPTER 2 
 
ELEVATED ANXIETY-LIKE BEHAVIOR FOLLOWING ETHANOL EXPOSURE IN 
MUTANT MICE LACKING NEUROPEPTIDE Y (NPY) 
 
 
Introduction 
Factors that may contribute to the initiation of ethanol consumption and/or 
continued use of this drug are high basal levels of anxiety and increased anxiety 
associated with ethanol withdrawal (Bibb and Chambless, 1986; Breese et al., 2005; 
Cappell and Herman, 1972; Cornelius et al., 2003; Koob, 2003; Schuckit and 
Hesselbrock, 1994). Viewed this way, excessive ethanol consumption and relapse 
drinking results from an attempt to self-medicate against the negative emotional 
responses that accompany ethanol withdrawal. Thus, identifying the neurochemical 
substrates that modulate withdrawal-induced anxiety may reveal pharmacological 
targets for treating alcohol abuse and relapse.  
An interesting candidate is neuropeptide Y (NPY), a 36-amino-acid 
neuromodulator belonging to the PP-fold family of peptides (Berglund et al., 2003; 
Colmer and Wahlestedt, 1993; Dumont et al., 1992) that is expressed throughout the 
central nervous system (Gray and Morley, 1986) and has been shown to modulate 
neurobiological responses to ethanol (Badia-Elder et al., 2001; Pandey et al., 2003a; 
Thiele et al., 2002; Thiele et al., 1998; Thiele et al., 2004). There are several 
observations that make NPY a likely candidate for modulating withdrawal-induced 
anxiety. First, NPY possesses anxiolytic properties when infused into the brain 
(Heilig et al., 1993; Heilig et al., 1989). Second, twenty-four hours after withdrawal 
from an ethanol-containing diet, rats show decreased NPY immunoreactivity in 
several brain regions including the central and medial nuclei of the amygdala (Roy 
and Pandey, 2002). Third, infusion of a protein kinase A (PKA) activator into the 
central nucleus of the amygdala, a treatment that causes increases of amygdalar 
NPY levels (Pandey et al., 2005), protects against withdrawal-induced anxiety in rats 
(Pandey et al., 2003b). The purpose of the present experiment was to use a genetic 
approach to study the role of NPY in modulating anxiety-like behavior stemming 
from exposure to and/or withdrawal from ethanol using mutant mice lacking 
production of NPY (NPY-/-) and normal wild-type mice (NPY+/+). 
 
Methods 
Animals 
Male and female NPY-/- (n = 15) and littermate NPY +/+ (n = 16) mice were 
maintained on an inbred pure 129/SvEv background and were developed as 
described elsewhere (Erickson et al., 1996). Because there were no significant 
differences between male and female mice, data are collapsed across sex within 
each of the analyses below. All mice were individually housed in plastic mouse 
cages with free access to standard rodent chow (Teklad, Madison, WI) and water 
except were noted. Mice were approximately 16 weeks of age at the start of each 
experiment. The colony room was maintained at approximately 22º C with a 12-hour 
light/dark cycle and lights off at 6:00 a.m. All procedures used in the present studies 
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were in compliance with the National Institute of Health guidelines, and all 
procedures were approved by the University of North Carolina Institutional Animal 
Care and Use Committee (IACUC). 
 
Liquid Ethanol Diet 
The diet used was a lactalbumin/dextrose-based, nutritionally complete diet 
with concentrations of vitamins, minerals and other nutrients derived from ICN 
Research Diets (Moy et al., 1997; Moy et al., 2000). Dextrose calories in the control 
diet (CD) were equated with ethanol calories in the ethanol diet (ED, 4.5%, w/v). 
Normal rodent chow was removed from the mouse cages during access to diet and 
water was provided in a second bottle. To reduce spillage, diet was presented to the 
mice in drinking bottles fitted with ball-point sipper tubes. Mice were first habituated 
with 3-days of access to CD and were given 6-days access to ED (NPY-/-, n = 7; 
NPY+/+, n = 8) or CD (NPY-/-, n = 8; NPY+/+, n = 8). Six-hours before testing, ED 
was replaced with CD in the ethanol-withdrawn groups (ED-WD). We chose to 
assess anxiety-like behavior 6-hours after removal of ethanol because we have 
found withdrawal-induced anxiety at this time point using the current diet protocol in 
rats (Knapp et al., 2004; Overstreet et al., 2002).  
 
Assessment of Anxiety Following Ethanol Withdrawal 
To assess anxiety-like behavior, mice were individually tested using elevated 
plus maze (EPM) procedures. Testing began at approximately 9:00 a.m., during the 
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dark cycle. The plus maze (MED Associates, Inc., St. Albans, Vermont) was 
positioned in the center of the room directly below a ceiling-mounted lamp fitted with 
a single 25-watt red light bulb which provided the only light for the room. Each 
mouse was placed onto the center square of the plus maze with its nose pointing 
towards one of the open arms. The 5-min test session was video recorded with a 
tripod-mounted camcorder. Sessions were scored by genotype-blind investigators 
for time spent (min), and the proportion of total time spent, in the open arm defined 
as open arm time divided by total time spent in both arms. An animal was 
considered to have entered an arm of the plus maze if all four paws had left the 
center square. Open and closed arm time was considered terminated once a single 
paw was placed back into the center square.  To determine possible group 
differences in locomotor activity, the total number of arm entries (open and closed) 
was also assessed.  
 
Data Analysis 
All data in are presented as mean + SEM. We used 2 x 2 (genotype x diet) 
analyses of variance (ANOVAs) to assess main effects and conducted t-tests (Winer 
et al., 1991) for planned comparisons. Significance was accepted at P < 0.05. 
 
Results 
NPY-/- and NPY+/+ mice that drank ED consumed 15.99 + 0.72 and 15.13 + 
0.65 g ethanol/kg per day, respectively. On the day of testing, ED-WD groups (NPY-
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/-, 22.72 + 1.13 g; NPY+/+, 22.78 + 0.76 g) had similar body weight compared to the 
CD groups (NPY-/-, 24.62 + 1.91 g; NPY+/+, 23.71 + 1.01 g). Figure 2.1 shows EPM 
data collected on time spent in open arms, proportion of time in spent open arms, 
and total arm entries. ANOVA performed on EPM data (Figure 2.1a) revealed a 
significant main effect of genotype [F(1, 27) = 6.20] on the time spent in the open 
arm of the plus maze, while an ANOVA performed on data representing the 
proportion of time spent in the open arm (Figure 2.1b) revealed a significant main 
effect of genotype [F(1, 27) = 4.81] and a significant genotype by diet interaction 
effect [F(1, 27) = 6.57]. While NPY-/- mice that were withdrawn from ethanol (ED-
WD) showed significantly less open arm time and proportion of open arm time 
relative to NPY-/- mice that drank the CD, there were no significant differences in 
anxiety-like behavior between NPY+/+ mice given CD or ED-WD treatment. 
Additionally, NPY-/- and NPY+/+ mice showed significant differences in open arm 
time and in the proportion of time spent in the open arm following the ED-WD 
treatment. However, there were no genotype differences in mice that had access to 
the CD. An ANOVA performed on total open arm entry data (Figure 2.1c) revealed 
no significant effects. 
 
Discussion 
Here we show that a lack of normal NPY production predisposes 129/SvEv 
mice to increased anxiety-like behavior stemming from exposure to and/or 
withdrawal from ethanol. Thus, ethanol-withdrawn NPY-/- mice showed significantly 
less open arm time and total proportion of time spent in the open arm of the EPM 
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relative to ethanol-withdrawn NPY+/+ mice, and when compared with NPY-/- and 
NPY+/+ mice that had access to the CD. On the other hand, ethanol-withdrawn 
NPY+/+ mice did not show altered EPM behavior relative to controls. Further, the 
altered EPM activity resulting from ethanol withdrawal in NPY-/- mice was not 
related to changes in locomotor activity as there were no group differences in total 
arm entries. Thus, these preliminary observations indicate that NPY-/- mice are 
more sensitive to the anxiety-like behavior associated with exposure to and/or 
withdrawal from ethanol.  
In the present study, groups that received continuous access to ethanol diet 
up to the EPM test were not employed. It is therefore possible that elevated anxiety-
like behavior by the NPY-/- mice in the ED-WD condition resulted from exposure to 
ethanol, rather than ethanol withdrawal per se. While we did not assess blood 
ethanol concentrations (BECs), a previous report found that 129/SvJ mice 
metabolize ethanol at a rate of 1.1 mg/dl/min (Homanics et al., 1998). At this rate, 
after 6-hours mice in the present experiment could have metabolized up to 396 
mg/dl, a BEC they were unlikely to have exceeded at the time ethanol was removed. 
Thus, it is unlikely that increased anxiety-like behavior by the NPY-/- mice was 
related to the presence of ethanol in the system at the time of EPM testing. 
Nonetheless, in the absence of BEC data and continuous ethanol access groups, a 
more conservative conclusion for the present work is that NPY-/- mice show 
increased anxiety-like behavior stemming from ethanol exposure, with the possibility 
that ethanol withdrawal contributes to this response.  
Here, wild-type 129/SvEv mice did not display increased anxiety-like behavior 
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6-hours following the removal of ethanol. It is possible that EPM testing at time 
points greater than 6-hours following ethanol withdrawal, more days with access to 
ethanol diet, and/or multiple cycles of ethanol access and withdrawal (Breese et al., 
2004; Knapp et al., 2004; Overstreet et al., 2002, 2004) may augment anxiety-like 
behavior in the wild-type mice. Such manipulations will be the subject of future 
studies. We predict that NPY-/- mice will continue to show increased anxiety-like 
behavior in all cases. Additionally, contrary to a previous observation (Palmiter et al., 
1998), NPY-/- mice in the CD condition did not show increased anxiety-like behavior 
relative to NPY+/+ mice. Although the reason for this discrepancy is unclear, 
different genetic background of NPY-/- mice in the present study (129/SvEv) and the 
previous work (C57BL/6J x 129/SvEv) may account for such differences. In fact, 
genetic background effects on ethanol-associated phenotypes in NPY-/- mice have 
previously been reported (Thiele et al., 2000). 
Because NPY-/- mice lack NPY throughout the central nervous system, we 
can only speculate on the brain region(s) in which NPY modulates anxiety-like 
behavior in NPY-/- mice of the present study. One candidate region is the amygdala. 
Infusion of NPY into the amygdala reduces anxiety-like behavior in rodents (Heilig et 
al., 1993; Sajdyk et al., 1999). Furthermore, NPY expression is blunted in the central 
and medial nuclei the amygdala of rats following ethanol withdrawal (Roy and 
Pandey, 2002), and infusion of a protein kinase A (PKA) activator into the central 
nucleus of the amygdala, a treatment that causes increases of amygdalar NPY 
levels (Pandey et al., 2005), protects against withdrawal-induced anxiety in rats 
(Pandey et al., 2003b). These observations provide convincing evidence that low 
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NPY signaling in the amygdala can modulate withdrawal-induced anxiety-like 
behavior, and suggest the possibility that a lack of NPY signaling in the amygdala of 
NPY-/- mice predisposes these animals to increased anxiety-like behavior following 
ethanol exposure and withdrawal. 
In conclusion, the present investigation reveals that NPY-/- mice show 
enhanced anxiety-like behavior stemming from ethanol exposure and/or withdrawal 
form ethanol, indicating that NPY-/- mice are a useful model for studying the role of 
NPY in modulating ethanol-associated anxiety-like responses. The present and past 
(Pandey et al., 2003b; Roy and Pandey, 2002) observations suggest that targets 
aimed at NPY receptors may be useful compounds for treating anxiety associated 
with ethanol exposure and withdrawal, and thus may be useful for preventing 
relapse that is triggered by withdrawal-induced anxiety or anxiety stemming from 
general life stressors (Breese et al., 2005). Because quantitative trait locus (QTL) 
analyses suggest that there are multiple candidate genes for the modulation of 
anxiety-like behavior, each revealed with different testing procedures (e.g., elevated 
plus maze, open field activity, etc.) (Henderson et al., 2004; Turri et al., 2001), 
additional studies are required for a more complete characterization of withdrawal-
induced anxiety-like behavior in NPY-/- mice. Important next steps also include a 
characterization of the time course of withdrawal-induced anxiety-like behavior, 
identifying the NPY receptors that are involved, determining sensitivity of the present 
phenotype to the genetic background of the NPY-/- mice, and identifying the brain 
regions in which NPY modulates withdrawal responses in these mice. 
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Figure 2.1 Elevated plus maze performance by NPY-/- and NPY+/+ mice following 
6-days of access to a control diet (CD) or 6-days of access to a 4.5% ethanol diet 
that was withdrawn and replaced with CD 6-hours before testing (ED-WD). Data 
from 5-min test sessions are expressed as time in seconds (a), the proportion of 
total time that was spent in the open arm (b), and the total number of arm entries (c). 
All values reported are mean + SEM. *NPY-/- mice in the ED-WD significantly 
different from all other groups (P < 0.05) 
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CHAPTER 3 
 
THE ALCOHOL DEPRIVATION EFFECT (ADE) IN C57BL/6J MICE IS OBSERVED 
USING OPERANT SELF-ADMINISTRATION PROCEDURES AND IS MODULATED 
BY CORTICOTROPIN RELEASING FACTOF (CRF) TYPE 1 RECEPTOR AND 
NEUROPEPTIDE Y (NPY) SIGNALING 
 
  
 
Introduction 
 In the previous chapter, we showed that neuropeptide Y (NPY) modulates 
ethanol withdrawal-induced anxiety-like behavior, a neurobiological response to 
withdrawal in dependent organisms.  Thus, like corticotropin releasing factor (CRF), 
NPY modulates neurobiological responses to ethanol withdrawal in a manner 
consistent with the allostasis model.  To further discover the roles of NPY and CRF 
in neurobiological responses to ethanol, here we determined if NPY and CRF are 
involved in modulating the increased ethanol drinking associated with the alcohol 
deprivation effect (ADE), a model of ethanol relapse-like behavior. 
 Alcohol relapse is a major problem in the treatment of alcoholism.  
Approximately 60-80% of abstinent alcoholics will relapse at one point in their 
lifetime (Barrick and Connors 2002; Chiauzzi 1991). Thus, understanding the 
neurobiology of relapse and associated behaviors is a critical step towards the 
development of drugs aimed at treating alcoholism. Relapse after long periods of 
abstinence is frequently associated with excessive, or uncontrolled, ethanol drinking 
(Holter et al. 2000). Recent procedures have been developed and validated as 
animal models of uncontrolled ethanol drinking. One procedure involves periodic 
deprivation from ethanol after which animals consume significantly more ethanol 
than they had consumed prior to the deprivation period.  This phenomenon has been 
labeled the ADE and is thought to model compulsive uncontrolled relapse drinking 
characteristic of alcohol dependent humans (Spanagel and Holter 1999). 
The ADE is a robust phenomenon evident in rats (Heyser et al. 1997; 
McKinzie et al. 1998; Wolffgramm and Heyne 1995), monkeys (Kornet et al. 1990; 
Sinclair 1971) and humans (Burish et al. 1981; Mello 1972). The ADE can be seen 
at ethanol deprivation intervals as short as 12-hours (Sinclair et al. 1989) or as long 
as 75-days (Sinclair, 1973), and has been shown to increase in magnitude and 
duration following multiple cycles of ethanol deprivation in alcohol preferring (P) rats 
and high alcohol drinking (HAD) rats (McKinzie et al. 1998; Rodd et al. 2003; Rodd-
Henricks et al. 2001; 2002a; b). Interestingly, the ADE is also evident in selectively 
bred alcohol non-preferring (NP) and low alcohol-drinking (LAD) rats (Bell et al. 
2004). Importantly, ADE ethanol drinking appears to be truly “uncontrolled” as rats 
will continue to drink increased amounts of ethanol that are adulterated with aversive 
tastes such as quinine (Spanagel et al. 1996).  
Although there is an abundance of evidence in the literature indicating that 
the ADE can be modeled in rats, few experiments have been conducted that attempt 
to explore the ADE in mice.  Using two-bottle (ethanol versus water) homecage 
ethanol preference procedures, hybrid C57BL/6 x CBA mice displayed ADE ethanol 
drinking after a 2-week (Cowen et al. 2003; Salimov and Salimova 1993a) and a 3-
day (Salimov and Salimova 1993b) ethanol deprivation period. However, another 
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report found the ADE in only half of the C57BL/6 x CBA mice studied, and an 
inverse ADE, indicative of decreased ethanol consumption following a deprivation 
period, was observed in the congenic A(R4) strain (Salimov et al. 1993; Salimov and 
Salimova 1993a). The ADE has also been observed in C57BL/6N mice using 
homecage two-bottle procedures (Cowen et al. 2003; Sanchis-Segura et al. 2006). 
However, with the exception of one report (Middaugh et al. 2000a), ADE drinking 
has not been studied in C57BL/6J mice, one of the most commonly used inbred 
strains of mice for studying neurobiological responses to ethanol. C57BL/6J mice 
exhibit high ethanol consumption (>10 g/kg per day) (Belknap et al. 1993), and as 
shown in Chapter 4, these mice can achieve pharmacologically relevant blood 
ethanol concentrations during limited ethanol access, drinking in the dark 
procedures (Rhodes et al. 2005). Because C57BL/6J mice are frequently used in 
ethanol consumption studies, one goal of the present report was to determine if the 
ADE could be observed in this inbred strain of mice.  
A second goal of the present report was to further characterize the 
neurochemical substrate involved in modulating the ADE.  Previous studies utilizing 
pharmacological approaches have implicated glutamate (Backstrom et al. 2004; 
Holter and Spanagel 1999; Sanchis-Segura et al. 2006; Spanagel et al. 1996; 
Vengeliene et al. 2005) and opioid (Holter et al. 2000) receptor signaling in ADE 
drinking.  As outlined in Chapter 1, two additional promising candidates are CRF and 
NPY. 
Corticotropin releasing factor (CRF) is a 41 amino acid polypeptide with high 
concentrations in the hypothalamus, the brainstem, and the amygdala (Swanson et 
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al. 1983). Both acute and chronic ethanol exposure activate central CRF (Koob et al. 
1993; Rasmussen et al. 2000; Rivier et al. 1984). Increased levels of CRF are 
observed in the amygdala during ethanol withdrawal (Merlo Pich et al. 1995) and the 
anxiogenic effect of ethanol withdrawal is reversed by CRF receptor antagonists 
(Breese et al. 2004; Knapp et al. 2004; Overstreet et al. 2004; Rassnick et al. 1993). 
Of critical interest, central infusion of the CRF receptor antagonist, D-Phe-CRF(12-14), 
has no effect on ethanol self-administration in nondependent rats but eliminates 
excessive ethanol drinking by rats made dependent with chronic exposure to ethanol 
vapor (Valdez et al. 2002). Additionally, stress-induced reinstatement of operant 
ethanol self-administration is blocked after administration of a CRF receptor 
antagonist and increased by central infusion of CRF (Le et al. 2000; Stewart 2004). 
Taken together, these data suggest that central CRF receptor signaling modulates 
ethanol drinking in dependent animals thus making CRF a possible candidate in the 
modulation of ADE drinking.  
NPY, as mentioned in the previous chapter, has been implicated in numerous 
neurobiological responses to ethanol.  To summarize, administration of ethanol and 
ethanol withdrawal alters central NPY expression in rodents (Bison and Crews, 
2003; Clark et al., 1998; Ehlers et al., 1998; Kinoshita et al., 2003; Roy and Pandey, 
2003; Thiele et al., 2003).  Voluntary ethanol consumption and resistance to the 
intoxicating effects of ethanol are inversely related to NPY levels (Thiele et al., 
1998).  Administration of NPY reduces ethanol consumption in P rats (Badia-Elder et 
al., 2001; 2003).  Recently, NPY has been implicated in ethanol withdrawal.  I.c.v. 
infusion of NPY attenuates ethanol-withdrawal responses in Wistar rats (Woldbye et 
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al., 2003), and we showed in Chapter 2 that NPY -/- mice exhibit increased 
withdrawal-induced anxiety-like behavior when compared to the wildtype controls, 
indicating that NPY signaling modulates heightened anxiety-like behavior stemming 
from withdrawal (Sparta et al., 2007).  To extend these observations, here we 
determined if NPY signaling also modulates increased relapse-like drinking 
associated with ADE procedures.   
To address the questions of this chapter, we examined the expression of the 
ADE in C57BL/6J mice that were pretreated with CP-154,526, a selective CRF1 
receptor antagonist. Next, we examined the acquisition of the ADE in NPY-/- and 
NPY+/+ mice that were maintained on a C57BL/6J genetic background. Results 
from the present experiments suggest a possible role for CRF and NPY signaling in 
the modulation of relapse-like ethanol drinking associated with the ADE. 
 
METHODS 
 
Effect of Blockade of the CRF1 receptor on the ADE 
Animals 
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor ME) were used in all 
experiments. Mice were 6-8 weeks old, weighed between 25-30 g at the start of all 
experiments and were single housed in polypropylene cages with corncob bedding 
and ad libitum access to food and water. Standard rodent chow (Teklad, Madison, 
WI) and water were available at all times except were noted. The vivarium rooms 
were maintained at an ambient temperature of 22º C with a 12- hour/12-hour light-
 31
dark cycle. All experimental procedures were approved by the University of North 
Carolina Animal Care and Use Committee (IACUC) and complied with the NIH 
Guide for Care and Use of Laboratory Animals (National Research Council, 1996).      
 
Drugs 
 CP-154,526 (butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)- 
7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine) was donated by Pfizer (Groton, CT), and 
was suspended in a vehicle of 0.5% carboxymethylcellulose (CMC).  CP-154,526 
displays high affinity for the CRF1 receptor (Ki < 10 nM) and blocks CRF-stimulated 
adenylate cyclase activity in rodent pituitary and cortical membranes (Lundkvist et al. 
1996; Schulz et al. 1996). Importantly, systemic injection of CP-154,526 blocks 
anxiety-like behavior stemming from ethanol withdrawal in rats (Breese et al. 2005b), 
suggesting that peripheral administration of this drug produces central effects. 
During operant training (see below), mice received daily intraperitoneal (i.p.) 
injections of 0.5% CMC (5 ml/kg) 30-minutes before operant sessions to habituate 
them to injection procedures. Injection site was alternated between sides (left or 
right) daily to minimize tissue damage.  
 
Operant Ethanol Self-Administration and Ethanol Deprivation Testing  
Operant self-administration experiments were conducted in sixteen modular 
mouse operant chambers (Med Associates, Georgia, VT) with dimensions of 21.6 x 
17.8 x 12.7 cm and a stainless steel grid floor. All chambers were housed in a 
sound-attenuating shell with a ventilation fan.  Liquid receptacles with nose-poke 
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sensors were located in the center of the right and left chamber walls and a stainless 
steel response lever was to the right of each receptacle. Liquid solutions (one lever 
produced water, the second lever produced sucrose or ethanol) were infused using 
10 ml plastic syringes which were mounted on programmable pump infusion pumps 
(PHM-100, 3.33 rpm). The pumps delivered 0.01 ml of solution per activation. A 
yellow stimulus light and a tone (80 dB) were activated when the sucrose/ethanol 
response lever was depressed. No stimulus light or tone occurred when the water 
lever was pressed. A single food pellet was placed inside the operant chamber 
during 2-hour test sessions. A house light inside the operant chambers was turned 
on for the duration of the test. Data recorded during each 2-hour operant session 
included the number of sucrose/ethanol and water responses (bar presses), the 
number of sucrose/ethanol and water reinforcers (pump activation), and ethanol 
intake (g/kg body weight). The operant chambers were interfaced to an IBM 
computer and all data were automatically recorded using Med Associates software 
(MED-PC for Windows®, Version IV). All operant sessions were completed in the 
light phase of the light/dark cycle.   
All mice (n = 32) were placed under a modified operant sucrose fading 
procedure (Samson 1986; Schroeder et al. 2003a,b). Briefly, mice were initially 
trained to press two operant levers. One lever resulted in the delivery of a 10% 
sucrose solution (w/v), the other lever delivered distilled water. Mice were allowed to 
respond for 10% sucrose or water for 4-days in 16-hour sessions in order to 
strengthen lever pressing behavior. Sessions were then reduced to 2-hours per day 
for 4-days. At this point and for the remainder of the experiment, mice were given 
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access to two bottles in their homecage (one containing water and the other 
containing an ethanol solution). The ethanol concentration presented in the 
homecage matched the concentration of ethanol being tested in the operant 
chambers. Thus, animals had access to ethanol for 24-hour per day during the 
ethanol training phase and during subsequent ADE procedures. This was done so 
that ethanol deprivation would only occur during the deprivation periods described 
below. Following stable responding, increasing concentrations of ethanol were 
introduced to the 10% sucrose solution every 2-days (2, 4, 8, and 10% ethanol 
(v/v)). Then, the sucrose concentration was reduced every 2-days (5, 2, and 0% 
sucrose) until mice were responding only for 10% ethanol. 
Once mice displayed stable responding for 10% ethanol (8 sessions), mice 
were not run in the operant chambers and homecage ethanol was removed for a 4-
day ethanol deprivation period. Mice were then tested in 2-hour operant sessions 
over 3 consecutive days and they were again given access to 10% ethanol in their 
homecage along with food and water. Following the third operant session, mice were 
again deprived of ethanol for 4-days and then given access to ethanol in the operant 
chambers and homecage for 3 consecutive days. This procedure involving 3-days of 
ethanol access and 4-days of ethanol deprivation was repeated for a total of 4-
deprivation cycles.  
 
Effect of CP-154,526 on Operant ADE Responding 
 Mice continued cycles of ethanol access (3-days) and deprivation (4-days) as 
described above. In the procedures below, mice were administered CP-154,526 in a 
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counterbalanced order. Immediately following the 5th deprivation cycle, mice were 
injected with one of three doses of CP-154,526 (0, 10, 20 mg/kg) mixed in 0.5% 
CMC 30-minutes prior to the start of the first operant session. Immediately following 
the next deprivation cycle, mice were injected with one of two doses of CP-154,525 
(0 or 10 mg/kg). We chose not to use the 20 mg/kg dose of CP-154,526 during the 
second administration because this dose suppressed ethanol and water self-
administration below baseline levels, indicating non-specific suppressive effects of 
this dose on operant behavior. 
 
Open-Field Locomotor Activity after i.p. Injection of CP-154,526 
 To determine whether CP-154,526 could impair motor activity, mice were 
tested in an open-field arena that automatically recorded activity via photo beam 
breaks (Harvard Apparatus, Inc., Holliston, MA). The open field arena measured 
40.64 cm by 40.64 cm by 30.48 cm and was made of clear Plexiglas. Several cm of 
corncob bedding were placed into the open field chamber to aid in cleaning and to 
prevent the buildup of odor. C57BL/6J mice were handled and injected with CMC 
daily for 7-days before activity testing. CMC or CP-154,526 (10 mg/kg) was 
administered to mice (n = 10/group) and then 30 minutes later mice were placed in 
the center of the locomotor activity chamber. Horizontal distance traveled (in meters) 
was recorded as an index of motor function during a 2-hour test session.  
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ADE Procedures with Sucrose Reinforcement 
To determine if increased responded resulting from the ADE procedures was 
specific to ethanol reinforcement, we ran an additional study in which a 1% sucrose 
(w/v) solution served as the reinforcer for one lever and water the reinforcer for the 
second lever. We chose a 1% sucrose solution in this case because this solution 
resulted in similar levels of operant responding as the 10% ethanol solution.  Male 
C57BL/6J mice (n = 15) were trained to press two operant levers, one lever resulted 
in the delivery of a 1% sucrose solution, the other lever delivered distilled water.  A 
yellow stimulus light and tone (80 dB) were activated when the sucrose response 
lever was depressed. No stimulus light or tone occurred when the water lever was 
pressed.  Briefly, mice were allowed to respond for 1% sucrose or water for 2-days 
in 12-hour sessions in order to strengthen lever pressing behavior. Sessions were 
then reduced to 2-hours per day for 4-days.  At this point and for the remainder of 
the experiment, mice were given access to two bottles in their homecage (one 
containing 1% sucrose and the other containing water) in order to match procedures 
for the ADE experiments. Once mice displayed stable responding for the 1% 
sucrose solution (4 sessions), mice were given a deprivation period from operant 
procedures and homecage sucrose was removed for 4-days.   Immediately following 
the 4-day deprivation period, mice were injected with one of two doses of CP-
154,526 (0, 10 mg/kg) mixed in 0.5% CMC 30-minutes prior to the start of the first 
operant session post-deprivation.  Following this session, mice were given access to 
the 1% sucrose solution in their homecage and were run for 2 more operant sucrose 
self-administration sessions (3 sessions total post deprivation). 
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Effect of CP-154,526 on Operant Sucrose Self-Administration  
To determine if CP-154,526 had a suppressive effect on general operant 
behavior, we examined whether this drug would significantly reduce high levels of 
responding when a 10% sucrose solution was used as the reinforcer during non-
deprivation operant sessions.  Male C57BL/6J mice (n = 16) were trained to press 
two operant levers, one lever resulted in the delivery of a 10% sucrose solution 
(w/v), the other lever delivered distilled water.  A yellow stimulus light and tone (80 
dB) were activated when the sucrose response lever was depressed. No stimulus 
light or tone occurred when the water lever was pressed.  Briefly, mice were allowed 
to respond for 10% sucrose or water for 1-days in a 16-hour sessions in order to 
strengthen lever pressing behavior. Sessions were then reduced to 2-hours per day 
for 6-days.  Mice did not receive homecage sucrose during the duration of this 
experiment.  Once mice displayed stable responding for the 10% sucrose solution (4 
sessions), mice were injected with one of two doses of CP-154,526 (0, 10 mg/kg) 
mixed in 0.5% CMC 30-minutes prior to the start of the first operant test session. 
 
Operant Ethanol Self-Administration and Ethanol Deprivation Testing without 
Habituation Injections 
 One possible concern is that the level of lever pressing and ethanol 
consumption in the initial experiments (Figs 3.1 and 3.2) was relatively low, as 
consumption over the 2-hour test was about 1.0 g/kg or less. We hypothesized that 
the stress associated with i.p. injections each test day may have attenuated lever 
responding. To address this issue, we conducted another ADE experiment in naïve 
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male C57BL/6J mice in the absence of i.p. injections.  Briefly, all mice (n = 32) were 
placed under the operant self-administration paradigm as explained above including 
homecage ethanol access.  Once stable responding occurred for the 10% ethanol 
solution, mice were not run in the operant chambers and homecage ethanol was 
removed for a 4-day ethanol deprivation period. Mice were then tested in 2-hour 
operant sessions over 3 consecutive days and they were again given access to 10% 
ethanol in their homecage along with food and water. 
 
Assessment of the ADE in NPY -/- and NPY +/+ Mice 
Animals 
Male and female NPY-/- and littermate NPY +/+ mice were maintained on an 
inbred pure C57BL/6J genetic background. All mice were individually housed in 
plastic mouse cages with free access to standard rodent chow (Teklad, Madison, 
WI) and water except were noted. Mice were approximately 16 weeks of age at the 
start of each experiment. The colony room was maintained at approximately 22º C 
with a 12-hour light/dark cycle and lights off at 6:00 a.m. All procedures used in the 
present studies were in compliance with the National Institute of Health guidelines, 
and all procedures were approved by the University of North Carolina (IACUC). 
 
Operant Ethanol Self-Administration and Ethanol Deprivation Testing  
All mice (n = 59) were placed under the modified ADE procedure similar to 
above with a few modifications. Briefly, mice were initially trained to press two 
operant levers. One lever resulted in the delivery of a 10% sucrose solution (w/v), 
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the other lever delivered distilled water. Mice were allowed to respond for 10% 
sucrose or water for 4-days in 16-hour sessions in order to strengthen lever pressing 
behavior. Sessions were then reduced to 2-hours per day for 4-days. At this point 
and for the remainder of the experiment, mice were given access to two bottles in 
their homecage (one containing water and the other containing an ethanol solution). 
The ethanol concentration presented in the homecage matched the concentration of 
ethanol being tested in the operant chambers. Thus, animals had access to ethanol 
for 24-hour per day during the ethanol training phase. Following stable responding, 
increasing concentrations of ethanol were introduced to the 10% sucrose solution 
every 4-days (2, 4, 8, and 10% ethanol (v/v)). Then, the sucrose concentration was 
reduced every 4-days (5, 2, and 0% sucrose) until mice were responding only for 
10% ethanol. 
Once mice displayed stable responding for 10% ethanol (7-sessions), mice 
were not run in the operant chambers and homecage ethanol was removed for a 4-
day ethanol deprivation period. Mice were then tested in 2-hour operant sessions 
over 3 consecutive days and they were again given access to 10% ethanol in their 
homecage along with food and water. Following the third operant session, mice were 
again deprived of ethanol for 4-days and then given access to ethanol in the operant 
chambers and homecage for 3 consecutive days. This procedure involving 3-days of 
ethanol access and 4-days of ethanol deprivation was repeated for a total of 3-
deprivation cycles.  
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Data Analysis 
All data in this report are presented as means + SEM. We used analyses of 
variance (ANOVA) to analyze data from each experiment. In accordance with a priori 
hypotheses, when significant effects were obtained, we performed planned 
comparisons with paired or independent t-tests.  Fisher’s LSD tests were also 
performed for planned comparisons when ANOVAs were not significant as a means 
of controlling type-1 error inflation (Winer et al. 1991). Significance was accepted at 
p < 0.05 (two-tailed). 
 
Results 
 
Operant Ethanol Self-Administration and Ethanol Deprivation Testing with 
Habituation Injections 
Fig. 3.1a depicts the mean lever responses for 10% ethanol (2-hour session) 
performed by C57BL/6J mice at baseline (last three sessions before the first ethanol 
deprivation cycle) and the three sessions of post-deprivation responding following 
deprivation cycles 1 and 4 (for the purpose of clarity, data following deprivation 
cycles 2 and 3 are not presented).  A two-way mixed-factor ANOVA run on 10% 
ethanol lever response data indicated a significant main effect of session [F(3,186) = 
22.42, p < 0.01] and a significant session x deprivation cycle interaction [F(3,186) = 
3.80, p = 0.01].  Following the 1st ethanol deprivation cycle, planned comparisons 
revealed that mice performed significantly more responses for 10% ethanol on the 
first post-deprivation session relative to baseline ethanol lever responding [t(31) = -
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3.49, p < 0.01]  Following the 4th ethanol deprivation cycle, the rate of ethanol lever 
pressing on the first, second, and third post-deprivation sessions were significantly 
higher when compared to the baseline ethanol lever responding [t(31) = -6.68, p < 
0.01; t(31) = -4.24, p < 0.01; t(31) = -3.17, p = 0.03, respectively].  Mean lever 
responses for water at baseline and during the 2-hour sessions are shown in Fig. 
3.1b. A two-way mixed-factor ANOVA run on water data indicated a significant main 
effect of session [F(3,186) = 16.95, p < 0.01] and a significant session x deprivation 
cycle interaction [F(3,186) = 5.24, p < 0.01].  Following the 1st ethanol deprivation 
cycle, planned comparisons revealed that water lever pressing on the first session of 
operant testing was significantly higher than the baseline water response rate [t(31) 
= -4.67, p < 0.01]. Following the 4th ethanol deprivation cycle, lever pressing for 
water on the first, second, and third post-deprivation sessions were significantly 
higher when compared to the baseline water lever responding [t(31) = -4.96, p < 
0.01; t(31) = -2.98, p = 0.01; t(31) = -2.82, p = 0.01, respectively].   
Figs. 3.1c and d present the amount of ethanol (g/kg) and water (ml/kg) 
consumed by mice, respectively. A two-way mixed-factor ANOVA run on ethanol 
consumption data revealed a significant main effect of session [F(3,186) = 21.11, p < 
0.01] and a significant session x deprivation cycle interaction [F(3,186) = 3.38, p = 
0.02].  Following the 1st ethanol deprivation cycle, mice consumed significantly more 
ethanol relative to baseline following the first post-deprivation session [t(31) = -3.39, 
p < 0.01].  Following the 4th ethanol deprivation cycle, mice consumed more ethanol 
relative to baseline during each of the three post-deprivation sessions [t(31) = -6.34, 
p < 0.01; t(31) = -4.07, p < 0.01; t(31) = -2.90, p < 0.01].  Similarly, a two-way mixed-
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factor ANOVA run on water consumption data revealed a significant main effect of 
session [F(3,186) = 16.81, p < 0.01] and a significant session x deprivation cycle 
interaction [F(3,186) = 4.81, p < 0.01].  Following the first deprivation cycle, mice 
showed elevated water consumption relative to baseline during the first post-
deprivation session [t(31) = -4.66, p < 0.01], and  following the 4th deprivation cycle 
water consumption was significantly elevated above baseline levels during each of 
the three sessions [t(31) = -4.48, p < 0.01; t(31) = -2.76, p = 0.01; t(31) = -2.55, p = 
0.02]. 
 
Effect of CP-154,526 on Operant ADE Responding 
Because analyses revealed that the counterbalanced order in which mice 
received the 0 or 10 mg/kg doses of CP-154,526 did not differentially influence 
operant behavior, the data for each dose were collapsed for the analyses below. Fig. 
3.2a depicts the mean lever responses for 10% ethanol (2-hour session) performed 
by C57BL/6J mice during baseline and on the first post-deprivation session in which 
mice were administered CP-154,526 (0, 10, 20 mg/kg) 30-minutes before operant 
testing. A one-way ANOVA comparing each of the four conditions was significant 
[F(3,93) = 6.044, p = 0.001]. Consistent with the ADE, mice showed significantly 
greater post-deprivation lever responding following administration of the vehicle 
when compared to their baseline ethanol lever response rate [t(55) = -2.07, p = 
0.044]. Importantly, there was no significant difference between baseline ethanol 
responding and post-deprivation ethanol responding when mice were administered 
the 10 mg/kg dose of CP-154,526 [t(57) = 0.933, p = 0.355]. However, the 20 mg/kg 
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dose of CP-154,526 significantly reduced 10% ethanol lever responding relative to 
baseline [t(40) = 2.458, p = 0.018]. Fig. 3.2b depicts the mean lever responses for 
water during baseline and on the first post-deprivation session following 
administration of CP-154,526 (0, 10, 20 mg/kg). A one-way ANOVA run on the data 
was significant [F(3,93) = 4.94, p = 0.003]. The vehicle treated group had a 
significantly greater number of water lever responses when compared to the baseline 
water lever response rate [t(55) = -2.18, p = 0.034]. Relative to baseline, there was 
no significant difference in water responding following treatment with the 10 mg/kg 
dose of CP-154,526 [t(57) = 0.258, p = 0.79].  However, the 20 mg/kg dose of CP-
154,526 significantly reduced water lever responding relative to baseline [t(40) = 
3.424, p = 0.001].  Finally, the 10 mg/kg dose of CP-154,526 did not significantly 
reduce open-field locomotor activity (15761 + 1614 meters/2-hours) relative to mice 
treated with CMC (16381 + 134.3 meters/2-hours) [t(18) = 1.041, p = 0.386]. 
 
ADE Procedures with Sucrose Reinforcement 
Figure 3.3a depicts the mean lever responses for 1% sucrose (2-hour 
session) performed by C57BL/6J mice during baseline and on the first three post-
deprivation sessions in which mice were administered CP-154,526 (0, 10 mg/kg) 30-
minutes before operant testing.  Repeated measures ANOVA revealed no significant 
main effects.  Figure 3.3b depicts the mean lever responses for water (2-hour 
session) performed by C57BL/6J mice during baseline and on the first three post-
deprivation sessions in which mice were administered CP-154,526 (0, 10 mg/kg) 30-
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minutes before operant testing.  Repeated measures ANOVA revealed no significant 
effects.    
 
Effect of CP-154,526 on Operant Sucrose Responding 
 Figure 3.4a depicts the mean lever responses for 10% sucrose (2-hour 
session) performed by C57BL/6J mice during the test session in which mice were 
administered CP-154,526 (0, 10 mg/kg) 30-minutes before operant testing.  
Independent t tests revealed no effect of the 10 mg/kg dose of CP-154,526 on 
sucrose responding [t(14) = -0.558, p = 0.586].  Additionally, the 10 mg/kg dose of 
CP-154,526 did not alter water responding relative to control [t(14) = -1.095, p = 
0.298] (Fig 3.4b).    
 
Operant Ethanol Self-Administration and Ethanol Deprivation Testing without 
Habituation Injections 
 Fig. 3.5a depicts the mean lever responses for 10% ethanol (2-hour session) 
performed by C57BL/6J mice at baseline (last three sessions before the first ethanol 
deprivation cycle) and the three sessions of post-deprivation responding following 
the first deprivation cycles.  A repeated measures ANOVA run on the data was 
significant [F(3,93) = 8.79, p < 0.01].   Following the ethanol deprivation cycle, 
planned comparisons revealed that mice performed significantly more responses for 
10% ethanol on the first post-deprivation session relative to baseline ethanol lever 
responding [t(31) = -4.49, p < 0.01].  Mean lever responses for water at baseline and 
during the 2-hour sessions are shown in Fig. 3.5b.  A one-way ANOVA run on the 
 44
data was significant [F(3,93) = 6.46, p = 0.01].   Following the ethanol deprivation 
cycle, planned comparisons revealed that water lever pressing on the first session of 
operant testing was significantly higher than the baseline water response rate [t(31) 
= -3.96, p = 0.01].  Figs. 3.5c and d present the amount of ethanol (g/kg) and water 
(ml/kg) consumed by mice, respectively.  A one-way ANOVA run on both data sets 
was significant [F(3,93) = 8.74, p < 0.01; F(3,93) = 5.96, p < 0.01].     Following the 
ethanol deprivation cycle, mice consumed significantly more ethanol relative to 
baseline following the first post-deprivation session [t(31) = -4.07, p < 0.01].   
Additionally, following the first deprivation cycle, mice showed elevated water 
consumption relative to baseline during the first post-deprivation session [t(31) = -
3.34, p = 0.02].  
 
The ADE in NPY-/- and NPY+/+ Mice   
 Repeated measures ANOVAs were performed on the NPY knockout data that 
assessed genotype x sex x days (2 x 2 x 4) for each deprivation cycle. However, 
within each analysis, neither the genotype nor sex factors were significant. 
Furthermore, neither the genotype nor sex factors significantly interacted with the 
days effect. Because a priori predictions were that NPY-/- mice would show 
enhanced ADE responding relative to NPY+/+ mice, and because it is well 
established in the literature that female C57BL/6J mice self-administer greater 
amounts of ethanol than male C57BL/6J mice (Meliska et al., 1995; Middaugh et al., 
1999), we used Fisher’s LSD tests as planned comparisons of baseline responding 
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to post-deprivation responding for each genotype and each sex during each of the 
deprivation cycles.  
Fig. 3.6a, b and c depicts the mean lever responses for 10% ethanol (2-hour 
session) performed by female NPY-/- and NPY+/+ mice at baseline (the average of 
the last three sessions before the first ethanol deprivation cycle) and the three 
sessions of post-deprivation responding following deprivation cycle 1 (3.5a), 
deprivation cycle 2 (3.6b), and deprivation cycle 3 (3.6c).  A Fisher’s LSD test 
revealed that the female NPY-/- mice showed significantly greater post-deprivation 
lever responding on post deprivation day 1 when compared to their baseline level of 
responding during all three deprivation cycles (p = 0.023; p = 0.025; and p = 0.05, 
respectively).  There were no significant differences between baseline levels of 
responding and post-deprivation responding in the female NPY +/+ mouse.   Fig. 
3.6c, d and e depicts the mean lever responses for water (2-hour session) performed 
by female NPY-/- and NPY+/+ mice at baseline (the average of the last three 
sessions before the first ethanol deprivation cycle) and the three sessions of post-
deprivation responding following deprivation cycle 1 (3.6c), deprivation cycle 2 
(3.6d), and deprivation cycle 3 (3.6e). Fisher’s LSD tests run on the data were not 
significant with one exception.  Female NPY-/- mice pressed significantly more on 
the water lever on the first post-deprivation session relative to baseline lever 
responding during deprivation cycle 3 (p = 0.043). 
Fig. 3.7a, b and c depicts the mean lever responses for 10% ethanol (2-hour 
session) performed by male NPY-/- and NPY+/+ mice at baseline (the average of the 
last three sessions before the first ethanol deprivation cycle) and the three sessions 
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of post-deprivation responding following deprivation cycle 1 (3.7a), deprivation cycle 
2 (3.7b), and deprivation cycle 3 (3.7c).   Fisher’s LSD tests revealed that male NPY 
+/+ mice demonstrated significantly greater post-deprivation lever responding on 
post deprivation day 1 when compared to their baseline ethanol lever response rate 
during deprivation cycle 1 (p = 0.014).  Male NPY-/- mice did not exhibit altered lever 
pressing for 10% ethanol during any deprivation cycle tested.  Fig. 3.7c, d and e 
depicts the mean lever responses for water (2-hour session) performed by the male 
NPY-/- and NPY+/+ mice at baseline (the average of the last three sessions before 
the first ethanol deprivation cycle) and the three sessions of post-deprivation 
responding following deprivation cycle 1 (3.7c), deprivation cycle 2 (3.7d), and 
deprivation cycle 3 (3.7e).  Fisher’s LSD tests revealed no significant differences.  
 
Discussion 
The goal of the present set of experiments was two-fold: First, we wanted to 
expand the literature by determining if C57BL/6J mice, a commonly used model in 
ethanol consumption research, are capable of expressing the ADE. We found that 
male C57BL/6J mice will show ADE behavior using a short-term (2-hour) operant 
self-administration paradigm. Thus, relative to baseline operant self-administration of 
ethanol, C57BL/6J mice show a significantly greater number of responses for 
ethanol following a 4-day ethanol deprivation period.  Furthermore, consistent with 
previous findings (Bell et al. 2004; McKinzie et al. 1998; Rodd et al. 2003; Rodd-
Henricks et al. 2001; 2002a; b), multiple cycles of ethanol access and deprivation 
augment the magnitude and duration of ADE behavior. Importantly, increased post-
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deprivation responding was specific to ethanol reinforcement as a 4-day deprivation 
period did not cause significant post-deprivation increases of responding when 
sucrose served as the reinforcer. 
A second goal of the present report was to determine if CRF1 receptor 
signaling and NPY signaling is involved in the expression of the ADE in C57BL/6J 
mice. Consistent with a role for the CRF1 receptor, i.p. administration of a 10 mg/kg 
dose of the CRF1 receptor antagonist, CP-154,526, 30-minutes before assessing 
ADE behavior significantly blocked the elevated lever responding for ethanol that 
was evident in mice treated with i.p. injection of the vehicle.  Additionally, female 
NPY -/- mice exhibited increased lever responding for ethanol reinforcement 
following each deprivation period, an effect that was not evident in female NPY+/+ 
mice or male mice of either genotype. These findings provide evidence that 
expression of the ADE in C57BL/6J mice may be modulated by CRF1 receptor and 
NPY signaling.  
It is important to note that the 10 mg/kg dose of CP-154,526 did not reduce 
ethanol lever responding below baseline levels or significantly alter open-field 
locomotor activity or lever presses for a sucrose reinforcer.  Additionally, a previous 
report found that this dose of CP-154,526 did not alter 2-hour food intake by 
C57BL/6J mice (Wang et al. 2001).  Importantly, the 10 mg/kg dose of CP-154,526 
did not alter sucrose responding after a sucrose deprivation period. Taken together, 
these observations limit the likelihood that the effects of the 10 mg/kg dose of CP-
154,526 on ADE responding were related to non-specific side-effects such as 
lethargy or motor impairment. However, the effects of the 20 mg/kg dose of CP-
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154,526 may have produced non-specific side-effects as this dose reduced ethanol 
responding below baseline and vehicle treated levels.  
It is of interest to consider some of the aspects associated with the ADE data 
in the present report. As noted above, the magnitude and duration of the ADE was 
increased following multiple cycles of access and deprivation. These observations 
are consistent with previous studies that show a strengthened ADE following 
multiple cycles of access and deprivation in rats (Bell et al. 2004; McKinzie et al. 
1998; Rodd et al. 2003; Rodd-Henricks et al. 2001; 2002a; b).  Additionally, daily 
habituation injections decreased ethanol responding in the ADE paradigm (Figs. 3.1, 
3.2 & 3.5).  There was a 2-fold increase in the number of ethanol lever presses as 
well as g/kg of ethanol consumed in mice that did not receive daily CMC injections, 
demonstrating that the current ADE procedures can promote high levels of ethanol 
consumption (approximately 2.0 g/kg/2-hour) in C57BL/6J mice (Fig 3.5).    This 
result is not surprising as a previous study has shown that i.p. injections can act as a 
stressor in C57BL/6 mice (Meijer et al., 2006).  Significant increases in ethanol 
responding was associated with significant increases in water responding (Figs. 3.1,  
3.2 & 3.5) in studies that examined the ADE. A likely explanation for this observation 
is that since ethanol is a diuretic, the increased motivation to gain access to water in 
mice with elevated ethanol self-administration may be due to thirst resulting from 
dehydration. Consistent with this argument, when sucrose (a non-diuretic) was used 
as the reinforcer, there was no post-deprivation increase of lever pressing for water 
(or sucrose) reinforcement. Alternatively, access to the operant chamber after a 
deprivation period may have caused general behavioral arousal thus promoting non-
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specific increases of all behavior, including those directed at the operant lever for 
water. Again, the observation that a 4-day deprivation period did not alter post-
deprivation lever pressing for sucrose or water reinforcement argues against the 
influence of post-deprivation arousal. Curiously, significant increases of post-
deprivation ethanol responding in the female NPY knockout mice were associated 
with significant increases of water responding at only 1 of 3 ADE observations. 
 In addition to demonstrating the ADE in male C57BL/6J mice using operant 
procedures, the present report adds to the ADE literature by providing evidence for a 
role of CRF1 receptor signaling in the modulation of uncontrolled ethanol self-
administration. The present findings are consistent with previous data that have 
revealed a role for CRF receptor signaling in ethanol dependence. First, increased 
levels of CRF are observed in the amygdala during ethanol withdrawal (Merlo Pich 
et al. 1995) while the anxiogenic effect of ethanol withdrawal is reversed by CRF 
receptor antagonists (Breese et al. 2004; Knapp et al. 2004; Overstreet et al. 2004; 
Rassnick et al. 1993). Second, central infusion of the CRF receptor antagonist, D-
Phe-CRF(12-14), has no effect on ethanol self-administration in nondependent rats but 
eliminates excessive ethanol drinking by rats made dependent with chronic 
exposure to ethanol vapor (Valdez et al. 2002). Third, stress-induced reinstatement 
of operant ethanol self-administration (an animal model of ethanol relapse) is 
blocked by administration of a CRF receptor antagonist and increased by central 
infusion of CRF (Le et al. 2000; Liu and Weiss 2002; Stewart 2004).  
We have also demonstrated a role for NPY in modulation of the ADE.  This is 
consistent with recent data which shows a role for NPY in ethanol dependence.  
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Administration of ethanol and ethanol withdrawal alter central NPY expression (Clark 
et al., 1998; Ehlers et al., 1998; Roy and Pandey, 2002).   I.c.v. infusion of NPY 
reduced ethanol consumption in Wistar rats that underwent intermittent ethanol 
vapor exposure (Thorsell et al., 2005b).  Importantly, viral-vector mediated 
overexpression of NPY prevented the development of increased ethanol drinking 
resulting from ADE procedures in Wistar rats (Thorsell et al., 2007). While the 
present results are consistent with the Thorsell et al., (2007) observations, our 
results suggest a modest contribution of NPY signaling to the ADE in C57BL/6J 
mice, a conclusion which is bolstered by the observation that male NPY-/- mice did 
not show enhanced post-deprivation increases of ethanol self-administration 
resulting from ADE procedures.  Sex differences were not unexpected since it is well 
established in the literature that female C57BL/6J mice drink significantly more 
ethanol relative to male C57BL/6J mice (Meliska et al., 1995; Middaugh et al., 1999). 
Furthermore, epistatic interactions between sex linked genes and mutation have 
been noted previously  (Blednov et al., 2003; Ferraro III et al., 2006; Rhodes et al., 
2005b; Susulic et al., 1995). In fact, we have found that female NPY-/- mice show 
greater sensitivity to the locomotor stimulant effects of ethanol relative to male NPY-
/- mice (Thiele et al., 2000). 
Taken together with the present results, a picture emerges such that CRF1 
receptor and NPY signaling appears to be part of a dynamic mechanism that is 
involved with the development of ethanol dependence stemming from repeated 
ethanol exposure and withdrawal, a mechanism illustrated by the recently proposed 
allostasis and “kindling”/stress models of drug dependence (Breese et al. 2005a; 
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Koob 2003; Koob and Le Moal 2001). According to the allostasis model, chronic 
exposure to stressors, including drugs, promote changes to the central processes 
that maintain the system’s “set point”. Uncontrolled ethanol drinking stemming from 
repeated abstinence and relapse evolves, in part, as a consequence of a 
hyperactive CRF system and weakened NPY system (Koob 2003). 
 In conclusion, we show here that the ADE can be modeled in C57BL/6J mice 
using a short-term (2-hour) operant self-administration paradigm. Importantly, we 
provide novel evidence that expression of the ADE in C57BL/6J mice may be 
modulated by the CRF1 receptor signaling, and perhaps to a lesser degree, NPY. 
However, given the possibility that developmental compensation in constitutive 
knockouts may mask or attenuate the expression of phenotypes (Gerlai, 2001), 
additional research using pharmacological manipulations is needed to further clarify 
the role of NPY in modulating increased ethanol self-administration associated with 
ADE procedures. These findings add to a growing body of literature implicating the 
CRF and NPY system in the progressive development of ethanol dependence 
stemming from repeated cycles of excessive ethanol consumption and withdrawal. 
Taken together, these observations suggest a possible therapeutic role for CRF1 
receptor antagonists and NPY agonists in the treatment of alcoholism and the 
prevention of alcoholism relapse.  
 
 
 
 
 
 
 
 52
Figure 3.1 Operant lever responses for 10% (v/v) ethanol (a) and water (b) during 
the 2-hour test sessions following the first 4-day break from operant procedures 
(Deprivation 1) and after the fourth 4-day break (Deprivation 4). Consumption of 
10% (v/v) ethanol (g/kg) (c) and water (ml/kg) (d) during the 2-hour test sessions 
following deprivations 1 and 4.  Baseline (BL) refers to the average of the last three 
sessions before the first break. All values are means + SEM. *p < 0.05 relative to 
baseline measures.     
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Figure 3.2 Operant lever responses for 10% (v/v) ethanol (a) and water (b) during 
the 2-hour test immediately following a 4-day break from operant procedures. Mice 
were given an intraperitoneal (i.p.) injection of the CRF1 receptor antagonist CP-
154,526 (0, 10, 20 mg/kg) 30-minutes before testing. Baseline (BL) refers to the 
average of the last three sessions before the first break. All values are means + 
SEM. *p < 0.05 relative to baseline measures.   
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Figure 3.3 Operant lever responses for 10% (w/v) sucrose (a) and water (b) during 
the 2-hour test sessions following a 4-day deprivation from operant procedures.  
Mice were given an intraperitoneal (i.p.) injection of the CRF1 receptor antagonist 
CP-154,526 (0, 10 mg/kg) 30-minutes before testing.   Baseline (BL) refers to the 
average of the last three sessions before the 4-day break were introduced. All 
values are means + SEM. *p < 0.05 relative to baseline measures. 
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Figure 3.4 Operant lever responses for 10% (v/v) sucrose (a) and water (b) during 
the 2-hour test.  Mice were given an intraperitoneal (i.p.) injection of the CRF1 
receptor antagonist CP-154,526 (0, 10 mg/kg) 30-minutes before testing.  All values 
are means + SEM.  
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Figure 3.5 Operant lever responses for 10% (v/v) ethanol (a) and water (b) during 
the 2-hour test sessions following a 4-day deprivation from operant procedures in 
mice that did not receive habituation injections. Consumption of 10% (v/v) ethanol 
(g/kg) (c) and water (ml/kg) (d) during the 2-hour test sessions following the break.  
Baseline (BL) refers to the average of the last three sessions before the 4-day break 
were introduced. All values are means + SEM. *p < 0.05 relative to baseline 
measures. 
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Figure 3.6 Operant lever responses for 10% (v/v) ethanol (a, b, c) and water (d, e, f) 
during the 2-hour test sessions following the first 4-day deprivation from operant 
procedures (Deprivation 1; a and d), the second 4-day deprivation from operant 
procedures (Deprivation 2; b and e), and the third 4-day deprivation from operant 
procedures (Deprivation 3; c and f) of the female NPY -/- and NPY+/+ mice.  
Baseline (BL) refers to the average of the last three sessions before the first break. 
All values are means + SEM. +p < 0.05 relative to baseline measures for the female 
NPY -/- mice. 
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Figure 3.7 Operant lever responses for 10% (v/v) ethanol (a, b, c) and water (d, e, f) 
during the 2-hour test sessions following the first 4-day deprivation from operant 
procedures (Deprivation 1; a and d), the second 4-day deprivation from operant 
procedures (Deprivation 2; b and e), and the third 4-day deprivation from operant 
procedures (Deprivation 3; c and f) of the male NPY -/- and NPY+/+ mice.  Baseline 
(BL) refers to the average of the last three sessions before the first break. All values 
are means + SEM. #p < 0.05 relative to baseline measures for the male NPY +/+ 
mice. 
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CHAPTER 4 
 
BLOCKADE OF THE CORTICOTROPIN RELEASING FACTOR (CRF) TYPE 1 
RECEPTOR ATTENUATES ELEVATED ETHANOL DRINKING ASSOCIATED WITH 
DRINKING IN THE DARK PROCEDURES 
 
 
Introduction 
 In the previous chapters, we have shown that neuropeptide Y (NPY) and 
corticotropin releasing factor (CRF) modulate withdrawal-induced anxiety-like behavior 
as well as ethanol relapse-like ethanol drinking.  According to a NIAAA data base, 
binge drinking increases the risk for developing alcoholism.  Therefore, our final set of 
experiments will examine the role of CRF on excessive or binge-like drinking as 
modeled by drinking in the dark (DID) procedures. 
Rodent models of alcoholism, including inbred and selectively bred strains, have 
been useful tools for identifying the genetic and neurobiological factors that underlie 
this disease.  However, in many cases rodents do not consume enough alcohol to 
reach the point of behavioral and/or pharmacological intoxication (Spanagel, 2000). 
Recently, “drinking in the dark” (DID) procedures have been developed to induce 
excessive ethanol drinking in C57BL/6J mice, which result in blood ethanol 
concentrations reaching levels that have measurable effects on physiology and/or 
behavior (Rhodes et al., 2005; Rhodes et al., 2007). With these procedures, C57BL/6J 
mice are given access to a 20% ethanol solution for 2 to 4-hours starting 3-hours into 
their dark cycle. C57BL/6J can achieve blood ethanol concentrations (BECs) of >100 
mg% and exhibit signs of behavioral intoxication as measured by motor deficits on the 
rotarod and balance beam (Rhodes et al., 2005; Rhodes et al., 2007).  It has been 
argued that the DID model has predictive validity for testing potential pharmacological 
targets aimed at treating alcohol abuse disorders as naltrexone, an opioid receptor 
antagonist currently used to treat alcoholism, dose dependently attenuates the high 
levels of ethanol drinking induced by DID procedures (Kamdar et al., 2007).   
 As seen in Chapter 3, CRF has been shown to modulate the neurobiological 
responses to ethanol as well as ethanol relapse.   To briefly summarize, increases in 
CRF immunoreactivity (Olive et al., 2002; Zorrilla et al., 2001) and levels of 
extracellular CRF (Funk et al., 2006) are seen in the amygdala following ethanol 
withdrawal. Exposure to ethanol causes robust activation of the hypothalamic-pituitary-
adrenal (HPA)-axis (Rivier, 1996; Rivier et al., 1990), which is initiated by ethanol-
induced increases of CRF activity within the hypothalamus (Li et al., 2005; Rivier and 
Lee, 1996). Recent pharmacological and genetic evidence support the hypothesis that 
CRF exerts its effects on ethanol consumption through activation of the CRF1 receptor.  
Blockade of the CRF1 receptor attenuates ethanol intake in dependent, but not non-
dependent, rodents (Funk et al., 2007; Gehlert et al., 2007).  Consistently, CRF1 
receptor deficient mice failed to show increased ethanol consumption following the 
acquisition of ethanol dependence and a period of abstinence that was observed in 
wild-type mice (Chu et al., 2007). Interestingly, a genetic polymorphism at the Crhr1 
locus, which encodes the CRF1 receptor was found to be significantly linked to 
alcoholism (Treutlein et al., 2006).   
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 Because CRF receptor signaling has been implicated in a wide range of 
neurobiological responses to ethanol, the goal of the present set of experiments was to 
determine whether the increased consumption of ethanol associated with DID 
procedures can be attenuated by pretreatment with CP-154,526, a CRF1 receptor 
antagonist.  Because blockade of CRF1 receptor signaling attenuates increased 
ethanol intake in ethanol-dependent rodents, we predicted that CRF1 receptor 
blockade would also attenuate increased ethanol drinking promoted by DID 
procedures.  
 
Methods 
Animals 
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor ME) were used in all 
experiments. Mice were 6-8 weeks old, weighed between 25-30 g at the onset of each 
experiment, and were single housed in polypropylene cages with corncob bedding. 
Standard rodent chow (Teklad, Madison, WI) and water were available at all times 
except where noted. The vivarium rooms were maintained at an ambient temperature 
of 22º C with a 12-hour/12-hour light-dark cycle.  Lights came on at 10:30 P.M. and 
went off at 10:30 A.M. All experimental procedures were approved by the University of 
North Carolina Animal Care and Use Committee (IACUC) and were in compliance with 
the NIH Guide for Care and Use of Laboratory Animals. 
 
Drugs 
CP-154,526 (butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)- 
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7H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethylamine) was donated by Pfizer (Groton, CT), and 
was suspended in a vehicle of 0.5% carboxymethylcellulose (CMC).  CP-154,526 
displays high affinity for the CRF1 receptor (Ki < 10 nM) and blocks CRF-stimulated 
adenylate cyclase activity in rodent pituitary and cortical membranes (Lundkvist et al., 
1996; Schulz et al., 1996). Importantly, peripheral administration of CP-154,526 has 
been shown to cross the blood-brain barrier and reach peak brain concentrations 20-
minutes after administration with significant levels of the drug observed in the cortex, 
striatum, cerebellum, and hippocampus (Keller et al., 2002). Additionally, i.p. injection 
of CP-154,526 in the dose range examined here appears to produce antidepressant-
like and anxiolytic-like effects in rodents (Breese et al., 2004; Chen et al., 1997; 
Lundkvist et al., 1996; Mansbach et al., 1997), data that suggest functional central 
actions of this drug. All concentrations of CP-154,526 used in the present experiment 
were mixed such that the final injection volume was 5 ml/kg. To habituate mice to 
procedures, all mice were handled and given intraperitoneal (i.p.) injections of CMC (5 
ml/kg) daily for approximately 7-days before the initiation of the experiments. The side 
of injection was switched daily in an attempt to limit discomfort and tissue damage. 
 
 DID After Administration of CP-154,526 with 4-Hour Training Sessions 
All mice (n = 39) underwent a modified DID protocol (Rhodes et al., 2005). 
Briefly, all homecage water bottles were replaced with a single bottle of 20% (v/v) 
ethanol, 3-hours into the start of the dark phase.  The 20% ethanol solution remained 
on the homecage for 4-hours.  All mice had ad libitum access to food during this time 
period.  After the 4-hour session, the 20% ethanol bottle was replaced with a bottle 
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containing water. On the first 3-days of this procedure, mice were given an i.p. injection 
of CMC 30-minutes prior to the presentation of the ethanol bottle. Mice were then 
distributed into 4-groups based on average ethanol consumption over the first 3-days 
of the experiment. On the fourth day, mice were given an i.p. injection of one of four 
doses of CP-154,526 (0, 1, 3, 10 mg/kg) mixed in CMC 30-minutes prior to the 
application of the ethanol bottle.  Immediately following the 4-hour test session, tail 
blood (6 µl) was collected from mice to determine BECs. 
 
DID After Administration of CP-154,526 with 2-Hour Training Sessions 
Procedures for this experiment were similar to those used in the previous 
experiment except that mice (n = 40) had access to the ethanol bottle for 2-hours 
(rather than 4-hours) during days 1-3. As above, mice were given an i.p. injection of 
CMC 30-minutes before access to ethanol, and mice were distributed to 4-groups 
based on average ethanol consumption over the first 3-days. On the fourth day, mice 
were injected with one of four doses of CP-154,526 (0, 1, 3, 10 mg/kg) mixed in CMC 
30-minutes prior to the application of the ethanol bottle.  Immediately following the 4-
hour test session, tail blood (6 µl) was collected from mice to determine BECs. This 
alternate DID procedure was used because Rhodes et al. (2005) found that shorting 
the length of ethanol access during the first 3-days of training led to greater ethanol 
consumption and greater BECs on the fourth day of access.  
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Open-Field Locomotor Activity after Administration of CP-154,526 
To determine whether CP-154,526 could impair locomotor activity, naïve male 
C57BL/6J mice (n = 20) were tested in an open-field arena that automatically recorded 
activity via photo beam breaks (Harvard Apparatus, Inc., Holliston, MA). The open field 
arena measured 40.64 cm by 40.64 cm by 30.48 cm and was made of clear Plexiglas. 
Several cm of corncob bedding were placed into the open field chamber to aid in 
cleaning and to prevent the buildup of odor. C57BL/6J mice were handled and injected 
with CMC daily for 7-days before activity testing. CMC or CP-154,526 (10 mg/kg) was 
administered to mice (n = 10/group) and then 30-minutes later mice were placed in the 
center of the locomotor activity chamber.  All mice were tested beginning 3-hours into 
the dark cycle to match DID procedures. Horizontal distance traveled (in centimeters) 
was recorded as an index of motor function during the 4-hour test session.  
 
Sucrose DID After Administration of CP-154,526 with 2 Hour Training Sessions 
To determine if a 10 mg/kg dose of CP-154,526 had a general suppressive 
effect on consummatory behavior, male C57BL/6J mice (n = 20) were tested with 
procedures similar to those used in the experiment with the 2-hour training sessions, 
except that the solution used for each 2-hour training session and the 4-hour test 
session was a 10% (w/v) sucrose solution. Mice were habituated to i.p. injections with 
CMC over 7-days and were also given i.p. injections of CMC on days 1-3. Mice were 
injected with CMC or a 10 mg/kg dose of CP-154,526 (n = 10/group) 30-minutes prior 
to the 4-hour test on day 4. 
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Blood Ethanol Concentrations After Administration of CP-154,526 
Blood ethanol samples were analyzed with gas chromatographic methods 
described elsewhere (Knapp et al., 1993; Navarro et al., 2003). Tail blood (6 μl) and 
standards (6 μl; 0-300 mg/100 ml) were mixed with 375 μl of distilled water and 0.5 g of 
NaCl in 12 × 75 mm borosilicate glass culture tubes. The tubes were capped and then 
heated at 55°C for 10-minutes in a water bath, at which point 1.5 ml of headspace gas 
was removed with a plastic 3.0 ml syringe and injected directly into an SRI 8610C gas 
chromatograph (Torrance, CA) equipped with an external syringe adapter and a 1.0 ml 
external loading loop. The oven temperature was isothermal at 140°C and contained a 
Hayesep D column and a flame ionization detector. Hydrogen gas, carrier gas (also 
hydrogen), and internal air generator flow rates were 13.3, 25, and 250 ml/minute, 
respectively. Peak retention time was 2-minutes, and the areas under the curve were 
analyzed with SRI PeakSimple software for Windows running on a Dell (Austin, TX) 
Inspiron 3500 laptop computer. 
 
Data Analysis 
All data in this report are presented as means + SEM. One-way analyses of 
variance (ANOVA) were used to analyze data from both drinking in the dark 
experiments. When significant main effects were obtained, Tukey’s HSD post hoc tests 
were performed for group comparisons (Winer et al., 1991).  Independent student’s t-
tests were performed to assess data from open-field locomotor activity and sucrose 
consumption. Significance was accepted at p < 0.05 (two-tailed).  
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Results 
DID After Administration of CP-154,526 with 4-Hour Training Sessions 
The volume of ethanol consumed (g/kg) and BECs achieved following the 4-
hours of access to ethanol on day 4 are presented in Fig. 4.1a and 4.1b, respectively. 
One-way ANOVAs preformed on these data revealed no significant effects of pre-
treatment with CP-154,526 on the amount of ethanol consumed [F(3,35) = 0.504, p = 
0.682] or BECs [F(3,35) = 0.829, p = 0.487].  
 
DID After Administration of CP-154,526 with 2-Hour Training Sessions 
The volume of ethanol consumed (g/kg) and BECs achieved following the 4-
hours of access to ethanol on day 4 are presented in Fig. 4.2a  and 4.2b, respectively. 
A one-way ANOVA performed on ethanol consumption data was significant [F(3,36) = 
4.961, p = 0.006].  Tukey’s HSD post hoc tests revealed that the 10mg/kg dose of CP-
154,526 significantly reduced ethanol consumption relative to the control group.  
Neither the 1 nor 3 mg/kg doses of CP-154,526 significantly altered ethanol 
consumption relative to the CMC treated group. A one-way ANOVA performed on BEC 
data was significant [F(3,36) = 4.493, p = 0.009], and Tukey’s HSD post hoc tests 
showed that the group treated with the 10mg/kg dose of CP-154,526 displayed 
significantly lower BECs relative to the CMC treated group. Groups pretreated with the 
1 or 3 mg/kg doses of CP-154,526 did not display BECs that were significantly different 
from the CMC treated group.   
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 Open-Field Locomotor Activity after Administration of  CP-154,526 
Data representing 4-hour locomotor activity following i.p. injection of CMC or a 
10 mg/kg dose of CP-154,526 are presented in Fig. 4.3.  An independent t-test 
performed on these data was not statistically significant [t(18) = 0.645, p = 0.527]. 
 
Sucrose DID After Administration of CP-154,526 with 2-Hour Training Sessions 
The volume of sucrose consumed (ml/kg) following the 4-hours of access to 
ethanol on day 4 are presented in Fig. 4.4.  An independent t-test performed on these 
data was did not achieve statistical significance [t(18) = 1.330, p = 0.205]. 
 
Discussion 
 Here we demonstrate that i.p. injection of a 10 mg/kg dose of CP-154,526, a 
selective CRF1 receptor antagonist, significantly attenuated ethanol consumption and 
BECs in C57BL/6J mice when DID procedures that promoted high levels of ethanol 
consumption (approximately 6.0 g/kg/4-hours) were employed. Interestingly, CP-
154,526 had no effect on ethanol consumption or BECs when DID procedures that 
promoted more moderate levels ethanol consumption (approximately 4.0 g/kg/4-hours) 
were employed.  These observations suggest high, but not moderate, levels of ethanol 
consumption induced by specific DID procedures are modulated by CRF1 receptor 
signaling. 
It was possible that the 10 mg/kg dose of CP-154,526 reduced ethanol 
consumption due to non-specific effects such impairment of motor function or general 
reductions of consummatory behavior. To determine the effects of CP-154,526 on 
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motor function, we examined the effects of the 10 mg/kg dose of CP-154,526 on 
locomotor activity 3-hours into the dark cycle and over a 4-hour test. The 10 mg/kg 
dose of CP-154,526 did not significantly alter 4-hour open-field locomotor activity, thus 
the ability of this dose of CP-154,526 to reduce ethanol drinking was unlikely related to 
effects of this drug on motor function. Importantly, pre-treatment with the 10 mg/kg 
dose of CP-154,526 did not influence 4-hour consumption of 10% sucrose when 
access began 3-hours into the dark cycle and this dose did not alter moderate ethanol 
consumption as seen in the DID experiment with 4-hour training sessions. Both 
observations suggest that reduced ethanol drinking induced by pre-treatment with CP-
154,526 is unlikely related to non-specific effects of this drug on consummatory 
behavior. Rather, it appears that CP-154,526 specifically modulates ethanol drinking 
when consumption levels are elevated. 
These data present novel evidence suggesting that CRF1 receptor signaling is 
involved with modulating high or excessive binge-like ethanol consumption in 
C57BL/6J mice that are induced by specific DID procedures. Interestingly, these 
observations parallel previous data where antagonism of CRF receptors attenuated 
increased ethanol drinking in rodents made dependent to ethanol by exposure to 
ethanol diet or ethanol vapor, but has no effect on moderate levels of ethanol 
consumption in non-dependent rodents (Finn et al., 2007; Sabino et al., 2006; Valdez 
et al., 2002). While ethanol drinking associated with DID procedures is unlikely to 
promote ethanol dependence to the degree achieved by exposure to ethanol vapor or 
ethanol-containing diets, the present findings, in tandem with previous work, suggest 
that CRF1 receptor signaling modulates increased ethanol drinking induced by a variety 
 69
of rodent models. Ethanol exposure induces activation of HPA-axis signaling (Rivier, 
1996; Rivier et al., 1990), an effect which is attenuated by pre-treatment with CRF 
receptor antagonists (Rivier and Lee, 1996). Because CP-154,526 has been shown to 
attenuate stress-induced activation of HPA-axis activity (Arborelius et al., 2000; Xu et 
al., 2005), it is tempting to speculate that increased ethanol drinking associated with 
DID procedures is mediated, in part, by an up-regulation of HPA-axis activity, an effect 
which may be prevented by pre-treatment with the CRF1 receptor antagonist. 
Consistently, treatment with corticosterone (a hormone that is secreted with HPA-axis 
activation) increases ethanol drinking by rodents, while inhibition of endogenous 
corticosterone synthesis or adrenalectomy suppresses ethanol consumption (Fahlke et 
al., 1995; Fahlke et al., 1996; Fahlke et al., 1994). The possible role of HPA-axis 
activity in the modulation of increased ethanol drinking with DID procedures, or if 
extrahypothalamic CRF signaling is involved, will be the topic of future research. 
Consistent with Rhodes et al., (2005), we show here that the level of ethanol 
consumption is sensitive to the specific DID procedures. Thus, the highest levels of 
ethanol consumption occurred when mice had 2-hours of access to ethanol during the 
first 3-days of the procedure and 4-hours of ethanol access on the final test day when 
BECs were assessed. With this procedure, mice achieved BECs of approximately 80 
mg%.  On the other hand, when mice had access to ethanol solution for 4-hours on 
each of the 4-days of the experiment, mice achieved BECs of approximately 30 mg%.  
However, despite higher levels of ethanol consumption, the level of ethanol 
consumption and the associated BECs were lower than those reported by Rhodes et 
al. (2005) using identical procedures and the same strain of mice. It is likely that subtle 
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environmental differences between laboratories are the bases of differences in the 
level of ethanol consumption between the present observations and those previously 
reported (Rhodes et al., 2005), as environmental factors have been demonstrated to 
have significant impact on behavioral measures (Crabbe et al., 1999; Wahlsten et al., 
2003). 
 A recent report found that both naltrexone and the dopamine re-uptake inhibitor 
GBR 12909 can attenuate increased ethanol consumption associated with DID 
procedures, suggesting a role for opioid and dopamine receptor signaling (Kamdar et 
al., 2007). The present observations add to this small but growing literature by 
demonstrating that CRF1 receptor signaling selectively modulates high ethanol drinking 
without altering moderate levels of ethanol consumption or sucrose drinking. Taken 
together, these observation suggest that the DID model may be an effective mouse 
model for rapid screening of pharmacological compounds aimed at treating alcoholism 
and alcohol abuse disorders.   
 In conclusion, this study demonstrates that i.p. administration of the systemically 
bioavailable and selective CRF1 receptor antagonist, CP-154,526, reduces excessive 
ethanol consumption caused by specific DID procedures.  These results are consistent 
with research showing that the CRF system modulates a spectrum of neurobiological 
responses to ethanol. Future research is needed to determine the brain regions in 
which CRF1 receptor signaling modulates increased ethanol drinking associated with 
DID procedures and if the CRF2 receptor plays a role.   
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Figure 4.1 Consumption of 20% (v/v) ethanol (a) and blood ethanol concentrations 
(BECs) (b) following the 4-hour ethanol consumption test on day 4 after 3-days of 4-
hour training. Mice were given intraperitoneal (i.p.) injection of the CRF1 receptor 
antagonist CP-154,526 (0, 1, 3, 10 mg/kg) 30-minutes before access to ethanol.  
There were no significant differences between treatment groups. All values are 
means + SEM.    
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Figure 4.2 Consumption of 20% (v/v) ethanol (a) and blood ethanol concentrations 
(BECs) (b) following the 4-hour ethanol consumption test on day 4 after 3-days of 2-
hour training. Mice were given intraperitoneal (i.p.) injection of the CRF1 receptor 
antagonist CP-154,526 (0, 1, 3, 10 mg/kg) 30-minutes before access to ethanol.  
Relative to mice treated with CMC, treatment with the 10 mg/kg dose of CP-154,526 
caused significant reduction of ethanol consumption and BECs. All values are 
means + SEM.   *p < 0.05 relative to the CMC treatment group.  
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Figure 4.3 Total locomotor activity (cm) during a 4-hour test following intraperitoneal 
(i.p.) injection of the CRF1 antagonist CP-154,526 (0, 0 mg/kg) 30-minutes before 
testing.  All values are means + SEM. *p < 0.05 relative to baseline measures.  
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Figure 4.4 Consumption of a 10% (w/v) sucrose solution following the 4-hour sucrose 
consumption test on day 4. Mice were given intraperitoneal (i.p.) injection of the CRF1 
antagonist CP-154,526 (0, 10 mg/kg) 30-minutes before access to sucrose. There was 
no significant difference between the two groups. All values are means + SEM.  
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CHAPTER 5 
GENERAL DISCUSSION 
 
 
 
Summary of Experimental Findings 
 In the present report, deletion of the NPY gene led to increased anxiety-like 
behavior stemming from ethanol exposure and/or withdrawal as measured by the 
elevated plus maze.  The difference in anxiety-like behavior was not due to motor 
impairment as both genotypes exhibited similar total open arm entries.  These data 
support established literature implicating NPY in general anxiety-like behavior and 
extends these findings by demonstrating a role for NPY in ethanol withdrawal-
induced anxiety (Bacchi et al., 2006; Heilig et al., 1989; 1993; Karlsson et al., 2005).  
To follow up on these experiments, we next examined the role of NPY in modulating 
the ADE, since withdrawal-induced anxiety is a major component of ethanol relapse 
and the ADE is thought to model relapse-like increases of ethanol drinking.  Female 
NPY -/- mice showed significantly elevated post-deprivation increases of ethanol 
intake relative to baseline levels, reflecting an ADE.  However, the ADE was not 
evident in female NPY+/+ mice, suggesting that a lack of NPY by female NPY-/- 
mice increased their sensitivity to deprivation-induced increases of ethanol self-
administration. The ADE in the female NPY-/- mice was observed at all three 
deprivation cycles.  However, neither male NPY-/- or NPY+/+ mice exhibited post-
deprivation increases of ethanol drinking at any deprivation cycle, suggesting the 
lack of an observed ADE.  These data indicate that lack of NPY may contribute 
modestly in the modulation of the ADE, however such a contribution appears to be 
dependent on the sex of the animal.  Together, these observations suggest that NPY 
signaling is involved with the neurobiological responses to ethanol withdrawal in 
ethanol-dependent mice, and may be a component of the neurobiological pathways 
that modulate relapse-like behaviors. Thus, these observations add to a growing 
body of literature suggesting a role of NPY in modulating neurobiological responses 
to ethanol (Badia-Elder 2001; 2003; Thiele et al., 1998). 
Our next set of experiments focused on the role of the CRF signaling system 
in modulating ADE-induced increases of ethanol intake.  These experiments were 
undertaken because NPY and CRF are hypothesized to exert a reciprocal regulation 
of ethanol self-administration through allosteric interactions within the extended 
amygdala, and there is a growing body of literature implicating the importance of 
CRF in modulating neurobiological responses to ethanol (Valdez and Koob, 2004).  
For these studies, we utilized CP-154,526, a highly selective CRF1 receptor 
antagonist.  This drug was chosen because it can be give peripherally and have 
effects centrally (Keller et al., 2002).  On the ADE test day, mice treated with the 
vehicle showed significantly greater levels of ethanol self-administration relative to 
baseline levels, indicating an ADE. However, acute administration of a 10 mg/kg 
dose of CP-154,526 before ADE testing decreased ethanol lever responding to 
baseline levels.  Importantly, administration of a 10 mg/kg dose of CP-154,526 did 
not result in altered sucrose self-administration or open-field locomotor activity, 
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indicating that it is unlikely that this compound reduced ADE ethanol self-
administration because of non-specific effects such as lethargy or impaired motor 
function. Finally, we determined if CP-154,526 would protect against binge-like 
ethanol drinking caused by DID procedures.   A 10 mg/kg dose of CP-154,526 
attenuated both ethanol consumption and BECs when DID procedures promoted 
significant elevations of ethanol drinking.  However it is important to note that the 10 
mg/kg dose of CP-154,526 did not alter moderate levels of drinking or consumption 
of sucrose arguing that CRF1 receptor signaling selectively modulates elevated 
ethanol consumption induced by specific DID procedures. Together these 
observations provide new evidence that CRF1 receptor signaling modulates relapse-
like increases of ethanol self-administration and is involved with binge-like drinking, 
characteristics of alcoholism and alcohol abuse that are thought to be modeled by 
ADE and DID procedures. 
The present set of experiments are consistent with the allostasis model of 
alcoholism dependence which posits that a hyperactive CRF system and a 
weakened NPY system are involved in the development of uncontrolled ethanol  
self-administration and an increased risk of relapse (Koob 2003; 2004; Valdez and 
Koob, 2004).  Ethanol withdrawal promotes a state of negative affect including 
anxiety-like behavior.  To assuage this anxiety, the alcoholic will relapse into a cycle 
of increased ethanol self-administration as modeled by the ADE.  Therefore any 
compound that would strengthen NPY signaling or attenuate CRF signaling, 
particularly the CRF1 receptor, would be a potential therapeutic target for the 
treatment of alcoholism.  Additionally, we found that the binge-like excessive ethanol 
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consumption is in part modulated by the CRF1 receptor. While it is not necessarily 
the case that individuals who binge drink ethanol are ethanol dependent, a growing 
body of literature suggest that frequent binge drinking increases the risk for 
becoming an alcoholic (McCarty et al., 2004, Mokdad et al., 2007; Stahre et al., 
2006).  The present results suggest that CRF1 receptor antagonist may have 
therapeutic value for treating binge drinking, and would thus reduce the risk for 
future ethanol dependence. 
 
Role of NPY and CRF in Ethanol Withdrawal-Induced Anxiety 
Withdrawal-induced anxiety has been implicated as an integral component of 
ethanol relapse in alcoholics (Hershon, 1977; Mossberg et al., 1985; De Soto et al.; 
1989; Parsons et al., 1990; Miller and Harris, 2000).  Approximately 80% of 
alcoholics consume alcohol due to feelings of anxiety and depression (Cloniger et 
al., 1987).  Additionally, alcoholics report negative affect as the most common cause 
of alcohol relapse (Annis et al., 1998).  Therefore, an understanding of the 
neurobiological mechanisms involved in the maintenance of withdrawal-induced 
anxiety would be of potential therapeutic value. 
Here we provide novel evidence that a lack of NPY signaling increases 
withdrawal-induced anxiety in mice, suggesting that NPY is protective.  Both male 
and female NPY -/- mice exhibit increased anxiogenic-like behavior when compared 
to the NPY +/+ controls following withdrawal from a liquid ethanol diet.  NPY has 
been linked to the modulation of anxiety-like behavior (Heilig et al., 1993; Heilig and 
Widerlove, 1995).  Centrally administered NPY will increase open arm time in the 
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elevated plus maze test and increase the number of shocks administered in the 
Vogel’s drinking conflict test (Heilig et al; 1989)  It appears that the extended 
amygdala is the primary target in the mediation of NPY’s effects on anxiety-like 
behavior.  Infusion of NPY directly into the amygdala reduces anxiety-like behavior 
in both the conflict test and the social interaction test (Heilig et al., 1993; Sajdyk et 
al. 1999).  During ethanol withdrawal, alterations in NPY immunoreactivity are 
observed in the brain (Bison and Crews, 2003; Ehlers et al., 1998).  Importantly, in 
the amygdala, a decrease in NPY protein levels are observed during ethanol 
withdrawal in the P rat (Roy and Pandey, 2002; Pandey et al., 2001; 2003b).    The 
anxiolytic effects of NPY in the amygdala also appear to be Y1 receptor mediated.  
Administration of BIBP3226, a NPY Y1 receptor antagonist, increased anxiogenic-
like behavior in rats in the elevated plus maze (Kask et al., 1998).  Additionally, 
antisense inhibition of the NPY Y1 receptor blocks the anxiolytic effects of NPY 
injected into the amygdala (Heilig, 1995).  Therefore, diminished NPY Y1 receptor 
signaling, primarily in the extended amygdala, is a likely candidate to modulate 
ethanol withdrawal-induced anxiety-like behavior. Future experiments will examine if 
withdrawal-induced anxiety is augmented in the NPY Y1 receptor -/- mice, and if 
virally mediated overexpression of NPY in the amygdala prevents NPY-/- mice from 
showing enhanced withdrawal-induced anxiety. 
 Although this report did not examine the effects of the CRF signaling system 
on withdrawal-induced anxiety, a plethora of research has shown that a hyperactive 
CRF system is involved in promoting anxiety (Altemus et al., 1994; Adinoff et al., 
1996; Bremner et al., 1997; Dunn and Berridge, 1990; Heinrichs et al., 1997)  Not 
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surprisingly, increases in CRF are also associated with increased anxiety-like 
behavior stemming from ethanol withdrawal (Overstreet et al., 2004; Timpl et al., 
1998).  Consistent with the NPY data, the extended amygdala has been implicated 
as a mechanism for the anxiogenic effects of CRF.  Ethanol withdrawn rats show an 
increase of extracellular CRF in the amygdala, which has been seen up to 6 weeks 
post withdrawal (Merlo-Pich et al., 1995; Zorilla et al., 2001).  Administration of 
alpha-helical CRF, a non-selective CRF antagonist, into the amygdala reduces 
anxiety-like behavior in rats undergoing withdrawal from a liquid ethanol diet 
(Rassnick et al., 1993).  Furthermore, the effects on anxiety appear to be CRF1 
receptor mediated, as administration of CRF1 receptor antagonists reduce 
withdrawal-induced anxiety-like behavior (Breese et al., 2005b; Overstreet et al., 
2004).  Therefore, pharmacological compounds that increase NPY Y1 receptor 
signaling or block the CRF1 receptor may be of potential clinical value for preventing 
the negative emotional state that is reported to accompany withdrawal and 
abstinence in human alcoholics. Since these negative emotional responses to 
withdrawal and abstinence are thought to trigger relapse, preventing such negative 
affect by NPY and CRF compounds could theoretically reduce the risk of relapse to 
alcohol abuse. 
The present report implicates both NPY and CRF as mediators of ethanol 
withdrawal-induced anxiety-like behavior.  Additional research has shown that other 
neurotransmitter systems mediate negative affect caused by ethanol withdrawal. 
The serotonin (5-HT) and gamma-aminobutyric acid (GABA) neurotransmitter 
systems have been implicated as well.  SB-243213, a 5HT2C receptor inverse 
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agonist injected into the amygdala reduced withdrawal-induced anxiety (Overstreet 
et al., 2006). Administration of diazepam and baclofen, both GABA receptor 
agonists, increase social interaction time in ethanol withdrawn rats (Knapp et al., 
2007).  Interestingly, in vitro studies show that NPY and CRF influence GABAergic 
neurotransmission in the extended amygdala (Kash and Winder, 2006).  Thus, NPY 
and CRF may modulate anxiety- and withdrawal-induced anxiety-like behavior via 
modulation of local GABAergic neurons within the amygdala. More research will be 
needed to elucidate this mechanism.      
 
Role of NPY and CRF on the ADE 
We have demonstrated a role for both the NPY and CRF system in 
withdrawal induced anxiety, a major component of ethanol relapse.  To extend these 
findings, we found that both NPY and CRF modulate increases ethanol drinking 
associated with ADE procedures, procedures designed to model excessive ethanol 
drinking associated with relapse.  NPY has already been implicated in the 
modulation of ethanol consumption (Sparta et al., 2004; Thiele et al., 1998; 2000; 
2002; 2003; Thorsell et al., 2005a, b).  We now show that NPY plays a modulatory 
role in ethanol relapse-like behavior, although the contributions of NPY, based on 
the results with NPY-/- mice, appears to be modest.  However, the current 
observations complement a recent finding which shows that virally-mediated 
overexpression of NPY in the amygdala reduces the ADE in rats (Thorsell et al., 
2007).  While CRF signaling system has been previously implicated in elevated 
ethanol self-administration in ethanol-dependent rodents (Funk et al., 2007; Valdez 
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et al. 2002), our results appear to be the first demonstration that CRF1 receptor 
signaling modulates the increased post-deprivation ethanol self-administration 
associated with ADE procedures. 
The ADE has been well established in the P rat, an animal that has been 
selectively bred to consume high levels of ethanol (McKinzie et al., 1998; Rodd-
Henricks et al., 2000; Sinclair and Li, 1989).  The ADE is a fairly robust 
phenomenon, as P rats will exhibit the ADE in both two bottle choice procedures and 
in operant self-administration studies (McKinzie et al., 1998; Sinclair and Li, 1989).  
The P rats are also an excellent comparison to our data because these rats have 
low levels of NPY in the amygdala and exhibit high basal anxiety-like behavior 
(Ehlers et al., 1998, Hwang et al., 1999; Stewart et al., 1993).  Importantly, 
ventricular infusion of NPY into the P rat reduces both anxiety-like behavior and high 
ethanol consumption (Badia-Elder et al., 2001; Gilpin et al., 2003).  Therefore it 
appears low NPY signaling, primarily in the amygdala, leads to increased anxiety-
like behavior, which in turn may contribute to relapse as measured by the ADE.  
Supporting this conclusion, overexpression of NPY in the amygdala blunted anxiety-
like behavior and ADE-induced increases of ethanol drinking in the P rat during 
ethanol withdrawal (Thiele et al., 2007). It must be noted that P rats exhibit low 
levels of CRF mRNA in the amygdala (Hwang et al., 2004).  However, this may be 
due to increased CRF release or an upregulation of CRF receptors in the P rat, 
which would contribute to the high anxiety and ethanol consumption seen in these 
animals.  Interestingly, a study has found that downregulated CRF is related to 
increased CRF receptor binding in rats (De Souza et al., 1985).       
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Previous research has shown that the glutametergic system contribute to the 
ADE.  Acamprosate was effective at reducing the ADE in operant procedures 
(Heyser et al., 2003).  LYY404039, a mGluR 2/3 agonist, reduced the ADE in rats 
(Rodd et al., 2006).  Activation of the mGluR 2/3 receptor reduces the excitatory 
effects of glutamate (Anwyl, 1999).  Additionally, GluR-C -/- mice exhibited an 
attenuated ADE (Sanchis-Segura et al., 2006).   These mice exhibit diminished 
AMPA activity. The present results extend these previous findings by showing that 
CRF and NPY signaling contributes the increased ethanol intake caused by ADE 
procedures. 
It is interesting to note that the male NPY-/- animals did not exhibit an ADE 
relative to NPY+/+ mice. As noted above, these observations indicate that the 
contributions of the NPY gene to the expression of the ADE depend on an epistatic 
interaction with other sex-linked genes, at least when NPY-/- mice are maintained on 
a C57BL/6J background. Such epistatic interactions between sex-linked genes and 
mutations have been noted previously.  For example, female NPY Y1 receptor -/- 
mice have increased body weight and greater increases in white adipose tissue 
when compared to female NPY Y1 receptor +/+ mice.  This result is not seen in the 
male NPY Y1 receptor -/- mouse (Kushi et al., 1998). Furthermore, we have noted 
that female NPY-/- mice show greater sensitivity to the locomotor stimulant effects of 
ethanol relative to male NPY-/- mice (Thiele et al., 2000).  On the other hand, 
enhanced withdrawal-induced anxiety-like behavior by NPY-/- mice was observed in 
both male and female mice.  It is important to note that the mice used in the 
withdrawal-induced anxiety study were maintained on 129/SvEv genetic background 
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(Sparta et al., 2007).  Thus, it is possible that an interaction between sex and 
mutation may be mouse background (C57BL/6J versus 129/SvEv) or phenotype 
(anxiety-like behavior versus deprivation-induced increases of ethanol drinking) 
dependent. 
 
Role of CRF in the Binge-Like Drinking Resulting from DID Procedures 
 The DID model is a relatively new paradigm, which produces excessive or 
binge-like drinking in C57BL/6 mice (Rhodes et al., 2005; 2007).  Mice will reach 
BECs of approximately 100 mg%, high enough for behavioral and pharmacological 
intoxication (Rhodes et al., 2005).  Previous research has implicated both the 
dopaminergic and opioid system in mediating the high ethanol consumption resulting 
from DID procedures (Kamdar et al., 2007).  Our data adds to this research by 
implicating a role for the CRF1 receptor binge-like ethanol consumption.  This is a 
novel finding as previous literature has shown that CRF receptor antagonists prevent 
increased ethanol intake in dependent rodents but are without effect in non-
dependent animals (Gehlert et al., 2007; Liu and Weiss, 2002, Valdez et al., 2002).  
Since our mice only had limited access to ethanol (4-days), they likely did not reach 
a stage of dependency similar to that induced by ethanol vapor or diet. The 
implication is the CRF1 receptor pathways that modulate dependence-induced 
drinking and binge-like drinking are not identical. 
 Based on the data, it appears the CRF system is recruited during bouts of 
excessive alcohol consumption.  Acute ethanol activates the hypothalamic-pituitary-
adrenal (HPA) axis, which is initiated by increases of CRF release (Rivier et al., 
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1984).   Activation of the HPA axis induces the release of corticosterone.  
Interestingly, administration of corticosterone increases drinking in rodents, while 
inhibition of endogenous corticosterone synthesis or adrenalectomy suppress ethanol 
consumption (Fahlke et al., 1995; Fahlke et al., 1996; Fahlke et al., 1994).  Therefore, 
it is possible that the high ethanol consumption induced by specific DID procedures 
may in part be driven by HPA axis signaling.  It is interesting to note that CP-154,526 
was not effective in reducing the moderate level of ethanol drinking.  This supports 
the idea that once a critical level of ethanol is consumed, the HPA axis is activated 
and modulates this high intake.  Although the effects of NPY on the DID model was 
not examined in the present report, pilot data in our laboratory indicates that mice 
treated with NPY saporin in the amygdala, a toxin that destroys neurons containing 
NPY receptors, exhibit increased ethanol consumption during DID testing. 
 Binge ethanol drinking, modeled by the DID procedure, could represent an 
important fist step into the development of alcoholism.  Thus, frequent episodes of 
binge drinking theoretically would promote plastic alterations of components within 
the extended amygdala.  According to the allostasis model, both NPY and CRF 
signaling are altered.  As binge drinking continues and the individual begins to move 
towards more regular excessive ethanol use, more pronounced and long-lasting 
changes to both NPY and CRF signaling results, ultimately inducing a chronic 
negative affective state which promotes uncontrolled excessive ethanol intake and 
increased risk for relapse. 
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Summary: NPY and CRF Modulate Multiple Neurobiological Responses to 
Ethanol 
 Previous research has implicated NPY and CRF in the neurobiological 
responses to ethanol (Koob, 2003, 2004; Funk et al., 2006; 2007; Thiele et al., 1998; 
2002; 2004).  However, with some exceptions, this work has focused primarily on 
the roles of these neuropeptides in modulating voluntary ethanol consumption or 
operant self-administration of ethanol. Thus, much less attention has been given to 
how NPY and CRF modulate neurobiological responses associated with ethanol 
dependence and withdrawal, relapse-like behaviors, and binge-like drinking.  This 
dissertation provides novel evidence by demonstrating that NPY and/or CRF 
modulate ethanol-withdrawal-induced anxiety, excessive ethanol drinking following 
forced abstinence (the ADE, a model of relapse associated drinking), and high levels 
of ethanol drinking when ethanol is given for a limited period of time during the dark 
cycle (a model of binge drinking).  These findings are important for several reasons.  
First, they demonstrate the usefulness of new rodent models of alcoholism and 
alcohol abuse for understanding how different neurochemical systems are involved 
in modulating the various facets of this disease.  Second, the present results extend 
previous work by showing that NPY and CRF are not only involved in voluntary 
ethanol intake, but in fact modulate multiple neurobiological responses to ethanol. 
Such observations may help expand the use of targets aimed at the NPY and CRF 
systems in treating not only alcoholism, but other behaviors, such as binge drinking, 
which increase the risk for becoming and alcoholic. 
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Future Directions 
 This dissertation presents novel evidence indicating that both the CRF and 
NPY signaling systems may be integral to both ethanol dependence (withdrawal) 
and relapse. These observations extend a growing body of literature suggesting that 
NPY and CRF modulate a range of neurobiological responses to ethanol.     We 
have provided evidence that the CRF1 receptor modulates CRF’s effects on 
increased relapse-like ethanol self-administration and excessive binge-like ethanol 
consumption in C57BL/6J mice.  Additionally, we have shown that deletion of the 
NPY gene increases withdrawal induced anxiety- and relapse-like ethanol intake.  
Taken together, these data support and add credence to the allostasis theory of 
alcoholism. 
Although this report focused on the CRF1 receptor, evidence has emerged 
implicating that the CRF2 receptor modulates the neurobiological responses to 
ethanol.  Activation of the CRF2 receptor decreases anxiety and ethanol self-
administration in withdrawn rats (Valdez et al., 2004).  Recently, administration of a 
CRF2 agonist into the amygdala was found to attenuate ethanol consumption in 
ethanol-dependent rats (Funk et al., 2007).  Future studies should examine the 
dichotomy of the two CRF receptors in regard to their differential effects on ethanol 
consumption.  We also did not examine the receptor subtypes involved in 
modulating NPY’s effects on the neurobiological responses to ethanol.  However, it 
appears the effects may be Y1 or Y2 receptor mediated.  NPY Y1 -/- mice consumed 
more ethanol than their wildtype controls, whereas the NPY Y5 -/- mice did not 
(Thiele et al., 2000, 2002).  NPY Y2 -/- mice consumed less ethanol than their 
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wildtype controls, and administration of a Y2 receptor antagonist reduced ethanol 
self-administration in rats (Rimondini et al., 2005; Thiele et al., 2004).  Although 
these results show differential effects for the Y1 and Y2 receptor, it should be noted 
that the Y2 receptor is a presynaptic autoreceptor, inhibiting release of NPY (King et 
al., 2000; Smith-White et al., 2001).  Therefore, it is possible that the Y1 and Y2 act in 
tandem in the extended amygdala modulating the effects of ethanol. Finally, it will be 
important to use pharmacological manipulations to further characterize the role the 
NPY may play in modulating increased relapse-like ethanol self-administration 
resulting from ADE procedures.   
In conclusion, evidence has revealed that the first wave treatments for 
alcoholism (disulfiram, naltrexone, acamprosate) are not effective for all patients.  
This has spurred the development of second and third wave compounds, which 
include drugs that target the NPY and CRF signaling systems.  Specifically, 
compounds that block the CRF1 receptor and strengthen NPY signaling may be of 
potential therapeutic value for treating alcoholism and relapse behaviors.  Animal 
models of human alcoholism will continue to be integral in testing of these 
compounds.  By examining the different components of alcoholism, we will be able 
target specific patient populations making treatments that much more effective.    
 
 
  
 
 
 
 
 
 
 89
REFERENCES 
 
Adinoff B, Anton R, Linnoila M, Guidotti A, Nemeroff CB, Bissette G (1996)  
 Cerebrospinal fluid concentrations of corticotropin-releasing hormone  
 (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and  
 abstinence.  Neuropsychopharmacology 15: 288-295 
 
Altemus M, Smith MA, Diep V, Aulakh CS, Murphy DL (1994) Increased mRNA  
 for corticotrophin releasing hormone in the amygdala of fawn-hooded rats:  
 a potential animal model of anxiety.  Anxiety 1: 251-257 
 
American Psychological Association (2000) Diagnostic and Statistical Manual of 
Mental Disorders DSM-IV-TR Fourth Edition. American Psychiatric 
Publishing, New York 
 
Annis HM, Sklar SM, Moser AE (1998) Gender in relation to relapse crisis situations, 
coping, and outcome among treated alcoholics.  Addict Behav 23: 127-131 
 
Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone 
and cognitive behavioral therapy for the treatment of outpatient alcoholics: 
results of a placebo-controlled trial. Am J Psychiatry 156: 1758-1764 
 
Anwyl R (1999) Metabotropic glutamate receptors: electrophysiological properties 
and role in plasticity.  Brain Res Brain Res Rev 29: 83-120
 
Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ (2000) 
Chronic administration of the selective corticotropin-releasing factor 1 receptor 
antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the 
rat. J Pharm Exp Ther 294: 588-597 
 
Bacchi F, Mathé AA, Jiménez P, Stasi L, Arban R, Gerrard P, Caberlotto L (2006) 
Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist 
BIIE0246 in the elevated plus-maze.  Peptides 27: 3202-3207 
 
Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R (2004) mGluR5 antagonist 
MPEP reduces ethanol-seeking and relapse behavior. 
Neuropsychopharmacology 29: 921-928 
 
Badia-Elder NE, Stewart RB, Powrozek TA, Roy KF, Murphy JM, Li TK (2001) Effect 
of neuropeptide Y (NPY) on oral ethanol intake in Wistar, alcohol-preferring 
(P), and -nonpreferring (NP) rats. Alcohol Clin Exp Res 25: 386-90 
 
Badia-Elder NE, Stewart RB, Powrozek TA, Murphy JM, Li TK (2003) Effects of 
neuropeptide Y on sucrose and ethanol intake and on anxiety-like behavior in 
high alcohol drinking (HAD) and low alcohol drinking (LAD) rats. Alcohol Clin 
Exp Res 27: 894-899 
 90
Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton KT (1991) CRF antagonist 
reverses the "anxiogenic" response to ethanol withdrawal in the rat. 
Psychopharmacology 103: 227-232 
 
Bale TL, Vale WW (2004) CRF and CRF receptors: role in stress responsivity and 
other behaviors.  Annu Rev Pharmacol Toxicol 44: 525-557
 
Barrick C, Connors GJ (2002) Relapse prevention and maintaining abstinence in 
older adults with alcohol-use disorders. Drugs Aging 19: 583-94 
 
Becker HC, Lopez MF (2004) Increased ethanol drinking after repeated chronic 
ethanol exposure and withdrawal experience in C57BL/6 mice.  Alcohol Clin 
Exp Res 28: 1829-1838 
 
Belknap JK, Crabbe JC, Young ER (1993) Voluntary consumption of ethanol in 15 
inbred mouse strains. Psychopharmacology 112: 503-510 
 
Bell RL, Rodd ZA, Boutwell CL, Hsu CC, Lumeng L, Murphy JM, Li TK, McBride WJ 
(2004) Effects of long-term episodic access to ethanol on the expression of 
an alcohol deprivation effect in low alcohol-consuming rats. Alcohol Clin Exp 
Res 28: 1867-74 
 
Berglund MM, Hipskind PA, Gehlert DR (2003) Recent developments in our 
understanding of the physiological role of PP-fold peptide receptor subtypes. 
Exp Biol Med 228: 217-244 
 
Bibb JL, Chambless DL (1986) Alcohol use and abuse among diagnosed 
agoraphobics. Behav Res Ther 24: 49-58 
 
Bice P, Foroud T, Bo R, Castelluccio P, Lumeng L, Li TK, Carr LG (1998) Genomic 
screen for QTLs underlying alcohol consumption in the P and NP rat lines. 
Mamm Genome 9: 949-955 
 
Biello, SM, Golombek, DA, Harrington, ME (1997) Neuropeptide Y and glutamate 
block each other's phase shifts in the suprachiasmatic nucleus in vitro, 
Neuroscience, 77:1049-1057 
 
Bienkowski P, Kostowski W, Koros E (1999) The role of drug-paired stimuli in 
extinction and reinstatement of ethanol-seeking behaviour in the rat.  Eur J 
Pharmacol 374: 315-319 
 
Bigelow GE, Griffiths RR, Liebson IA (1977) Pharmacological influences upon 
human ethanol self-administration.  Adv Exp Med Bio 85B: 523-538 
 
Bison S, Crews FT (2003) Alcohol withdrawal increases neuropeptide Y 
immunoreactivity in rat brain. Alcohol Clin Exp Res 27: 1173-1183 
 91
Blednov YA, Stoffel M, Alva H, Harris RA (2003) A pervasive mechanism for 
analgesia: activation of GIRK2 channels.  Proc Natl Acad Sci U S A 100: 277-
282
 
Bloom FE, Battenberg EL, Rivier J, Vale W (1982) Corticotropin releasing factor (CRF): 
immunoreactive neurones and fibers in rat hypothalamus. Regul Pept 4: 43-48 
 
Brady KT, Sonne SC (2005) The relationship between substance abuse and bipolar 
disorder.  J Clin Psychiatry 56 Suppl 3: 19-24 
 
Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff 
CB, Charney DS (1997) Elevated CSF corticotropin-releasing factor 
concentrations in posttraumatic stress disorder.  Am J Psychiatry 154: 624-
629
 
Breese GR, Knapp DJ, Overstreet DH (2004) Stress sensitization of ethanol 
withdrawal-induced reduction in social interaction: inhibition by CRF-1 and 
benzodiazepine receptor antagonists and a 5-HT1A-receptor agonist. 
Neuropsychopharmacology 29: 470-82 
 
Breese GR, Overstreet DH, Knapp DJ (2005a) Conceptual framework for the 
etiology of alcoholism: a "kindling"/stress hypothesis.  Psychopharmacology 
178: 367-380 
 
Breese GR, Overstreet DH, Knapp DJ, Navarro M (2005b) Prior multiple ethanol 
withdrawals enhance stress-induced anxiety-like behavior: inhibition by 
CRF1- and benzodiazepine-receptor antagonists and a 5-HT1a-receptor 
agonist. Neuropsychopharmacology 30: 1662-1669 
 
Breslau N, Davis GC, Schultz LR (2003) Posttraumatic stress disorder and the 
incidence of nicotine, alcohol, and other drug disorders in persons who have 
experienced trauma.  Arc Gen Psychiatry 60: 289-294 
 
Burish TG, Maisto SA, Cooper AM, Sobell MB (1981) Effects of voluntary short-term 
abstinence from alcohol on subsequent drinking patterns of college students. 
J Stud Alcohol 42: 1013-20 
 
Cappell H, Herman CP (1972) Alcohol and tension reduction. A review. Q J Stud 
Alcohol 33: 33-64 
 
Carr LG, Foroud T, Bice P, Gobbett T, Ivashina J, Edenberg H, Lumeng L, Li T.-K 
(1998) A quantitative trait locus for alcohol consumption in selectively bred rat 
lines. Alcohol Clin Exp Res 22: 884-887 
 
 92
Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB (1996) 
Corticotrophin-releasing factor receptors: from molecular biology to drug 
design.  Trend Pharmacol Sci 17: 166-172 
 
Chen R, Lewis KA, Perrin MH, Vale WW (1993) Expression cloning of a human 
corticotropin-releasing-factor receptor.  Proc Natl Acad Sci U S A 90: 8967-
8971
 
Chen YL, Mansbach RS, Winter SM, Brooks E, Collins J, Corman ML, Dunaiskis AR, 
Faraci WS, Gallaschun RJ, Schmidt A, Schulz DW (1997) Synthesis and oral 
efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active 
corticotropin-releasing factor1 receptor antagonist. J Med Chem 40: 1749-1754 
 
Chiamulera C, Valerio E, Tessari M (1995) Resumption of ethanol-seeking 
behaviour in rats.  Behav Pharmacol 6: 32-39 
 
Chiauzzi EJ (1991) Preventing releapse in the addictions: a biopsychosocial 
approach. Pergamon Press, New York 
 
Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, 
Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B (2000) A multicentre, 
randomized, double-blind, placebo-controlled trial of naltrexone in the 
treatment of alcohol dependence or abuse.  Alcohol 35: 587-593 
 
Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ (2007) Dependence-induced 
increases in ethanol self-administration in mice are blocked by the CRF1 
receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol 
Biochem Behav 86: 813-821 
 
Ciccocioppo R, Angeletti S, Weiss F (2001) Long-lasting resistance to extinction of 
response reinstatement induced by ethanol-related stimuli: role of genetic 
ethanol preference.  Alcohol Clin Exp Res 25: 1414-1419 
 
Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, Massi M 
(2004) Attenuation of ethanol self-administration and of conditioned 
reinstatement of alcohol-seeking behaviour by the antiopioid peptide 
nociceptin/orphanin FQ in alcohol-preferring rats.  Psychopharmacology 172: 
170-178 
 
Ciccocioppo R, Lin D, Martin-Fardon R, Weiss F (2003) Reinstatement of ethanol-
seeking behavior by drug cues following single versus multiple ethanol 
intoxication in the rat: effects of naltrexone.  Psychopharmacology 168: 208-
215 
 
 93
Ciccocioppo R, Martin-Fardon R, Weiss F (2002) Effect of selective blockade of 
mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior 
by drug-associated stimuli in rats.  Neuropsychopharmacology 27: 391-399 
 
Cicero TJ (1979) In: Majchrowicz E, Noble EP (eds) Biochemistry and 
Pharmacology of Ethanol, vol. 2. Plenum Press, New York, pp. 533-560 
 
Clark, JT, Kalra, PS, Crowley, WR, Kalra, SP (1984) Neuropeptide Y and human 
pancreatic polypeptide stimulate feeding behavior in rats, Endocrinology 115: 
427-429 
 
Clark JT, Keaton AK, Sahu A, Kalra SP, Mahajan SC, Gudger JN (1998) 
Neuropeptide Y (NPY) levels in alcoholic and food restricted male rats: 
implications for site selective function.  Regul Pept 75-76: 335-345 
 
Cloninger CR (1987) A systematic method for clinical description and classification 
of personality variants.  A proposal.  Arch Gen Psychiatry 44: 573-588 
 
Collins BN, Brandon TH (2002) Effects of extinction context and retrieval cues on 
alcohol cue reactivity among nonalcoholic drinkers.  J Consult Clin Psychol 
70: 390-397 
 
Colmer WF, Wahlestedt C (1993) The biology of neuropeptide Y and related 
peptides. Humana Press, New York 
 
Colombo G (1997) ESBRA-Nordmann 1996 Award Lecture: ethanol drinking 
behaviour in Sardinian alcohol-preferring rats.  Alcohol 32: 443-453. 
 
Cornelius JR, Bukstein O, Salloum I, Clark D (2003) Alcohol and psychiatric 
comorbidity. Recent Dev Alcohol 16: 361-74 
 
Coste SC, Heard AD, Phillips TJ, Stenzel-Poore MP (2006) Corticotropin-releasing 
factor receptor type 2-deficient mice display impaired coping behaviors during 
stress.  Genes Brain Behav 5: 131-138 
 
Cowen MS, Schroff KC, Gass P, Sprengel R, Spanagel R (2003) Neurobehavioral 
effects of alcohol in AMPA receptor subunit (GluR1) deficient mice.  
Neuropharmacology 45: 325-333 
 
Cox WM, Yeates GN, Regan CN (1999) Effects of alcohol cues on cognitive 
processing in heavy and light drinkers.  Drug Alcohol Depend 55: 85-89 
 
Crabbe JC, Wahlsten D, Dudek BC (1999) Genetics of mouse behavior: interactions 
with laboratory environment. Science 284: 1670-1672 
 
 94
Dautzenberg FM, Dietrich K, Palchaudhuri MR, Spiess J (1997) Identification of two 
corticotropin-releasing factor receptors from Xenopus laevis with high ligand 
selectivity: unusual pharmacology of the type 1 receptor.  J Neurochem 69: 
1640-1649 
 
De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ (1985) 
Corticotropin-releasing factor receptors are widely distributed within the rat 
central nervous system: an autoradiographic study.  J Neurosci 5: 3189-3203 
 
de Wit H (1996) Priming effects with drugs and other reinforcers. Exp Clin 
Psychopharmacol 4: 5-10 
 
De Soto CB, O'Donnell WE, De Soto JL (1989) Long-term recovery in alcoholics.  
Alcohol Clin Exp Res 13: 693-697 
 
Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R (1992) Neuropeptide Y and 
neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog 
Neurobiol 38: 125-167 
 
Dunn AJ, Berridge CW (1990) Physiological and behavioral responses to 
corticotropin-releasing factor administration: is CRF a mediator of anxiety or 
stress responses?  Brain Res Brain Res Rev 15: 71-100
 
Ehlers CL, Somes C, Cloutier D (1998) Are some of the effects of ethanol mediated 
through NPY?, Psychopharmacology 139: 136-144 
 
Erickson JC, Clegg KE, Palmiter RD (1996) Sensitivity to leptin and susceptibility to 
seizures of mice lacking neuropeptide Y. Nature 381: 415-418 
 
Eriksson K (1968) Ethyl alcohol consumption: valid measurement in albino rats.  
Science 161: 76-77. 
 
Fahlke C, Hard E, Eriksson CJ, Engel JA, Hansen S (1995) Consequence of long-term 
exposure to corticosterone or dexamethasone on ethanol consumption in the 
adrenalectomized rat, and the effect of type I and type II corticosteroid receptor 
antagonists. Psychopharmacology 117: 216-224 
 
Fahlke C, Hard E, Hansen S (1996) Facilitation of ethanol consumption by 
intracerebroventricular infusions of corticosterone. Psychopharmacology  127: 
133-139 
 
Fahlke C, Hard E, Thomasson R, Engel JA, Hansen S (1994) Metyrapone-induced 
suppression of corticosterone synthesis reduces ethanol consumption in high-
preferring rats. Pharmacol Biochem Behav 48: 977-981 
 
 95
Ferraro FM 3rd, Sparta DR, Knapp DJ, Breese GR, Thiele TE (2006) Increased 
consumption but not operant self-administration of ethanol in mice lacking the 
RIIbeta subunit of protein kinase A.  30: 825-835 
 
Finn DA, Snelling C, Fretwell AM, Tanchuck MA, Underwood L, Cole M, Crabbe JC, 
Roberts AJ (2007) Increased drinking during withdrawal from intermittent 
ethanol exposure is blocked by the CRF receptor antagonist D-Phe-CRF(12-
41). Alcohol Clin Exp Res 31: 939-949 
 
Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, 
Lacoursiere RB, Lee KK, Lowenstam I, et al (1986) Disulfiram treatment of 
alcoholism. A Veterans Administration cooperative study.  JAMA 256: 1449-
1455 
 
Funk CK, O'Dell LE, Crawford EF, Koob GF (2006) Corticotropin-releasing factor within 
the central nucleus of the amygdala mediates enhanced ethanol self-
administration in withdrawn, ethanol-dependent rats. J Neurosci 26: 11324-
11332 
 
Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007) Corticotropin-releasing factor 
1 antagonists selectively reduce ethanol self-administration in ethanol-
dependent rats. Biol Psychiatry 61: 78-86 
 
Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C, Lu J, Hembre 
EJ, Cramer J, Song M, McKinzie D, Morin M, Ciccocioppo R, Heilig M (2007) 3-
(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl- 
imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-
releasing factor receptor 1 antagonist with efficacy in animal models of 
alcoholism. J Neurosci 27: 2718-2726 
 
Gerlai R (2001) Gene targeting: technical confounds and potential solutions in 
behavioral brain research.  Behav Brain Res 125: 13-21 
 
Gilpin NW, Stewart RB, Murphy JM, Li TK, Badia-Elder NE (2003) Neuropeptide Y 
reduces oral ethanol intake in alcohol-preferring (P) rats following a period of 
imposed ethanol abstinence.  Alcohol Clin Exp Res 27: 787-794  
 
Golombek, DA, Biello, SM, Rendon, RA, Harrington, ME (1996) Neuropeptide Y 
phase shifts the circadian clock in vitro via a Y2 receptor, Neuroreport, 7: 
1315-1319 
 
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W (2004) 
Prevalence and co-occurrence of substance use disorders and independent 
mood and anxiety disorders: results from the National Epidemiologic Survey on 
Alcohol and Related Conditions.  Arch Gen Psychiatry 61: 807-816 
 
 96
Gray TS, Morley JE (1986) Neuropeptide Y: anatomical distribution and possible 
function in mammalian nervous system. Life Sci 38: 389-401 
 
Gribkoff, VK, Pieschl, RL, Wisialowski, TA, van den Pol, AN, Yocca, FD (1998) 
Phase shifting of circadian rhythms and depression of neuronal activity in the 
rat suprachiasmatic nucleus by neuropeptide Y: mediation by different 
receptor subtypes, J Neurosci 18: 3014-3022 
 
Hansel DE, Eipper BA, Ronnett GV (2001a) Neuropeptide Y functions as a 
neuroproliferative factor. Nature 410: 940-944 
 
Hansel DE, Eipper BA, Ronnett GV (2001b) Regulation of olfactory neurogenesis by 
amidated neuropeptides. J Neurosci Res 66: 1-7 
 
Harrington ME, Schak KM (2000) Neuropeptide Y phase advances the in vitro 
hamster circadian clock during the subjective day with no effect on phase 
during the subjective night. Can J Physiol Pharmacol 78: 87-92 
 
Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu 
MC, Hart SR, Pedigo NW, Littleton JM (2002) Acamprosate inhibits the 
binding and neurotoxic effects of trans-ACPD, suggesting a novel site of 
action at metabotropic glutamate receptors. Alcohol Clin Exp Res 26: 1779-
1793 
 
Heilig M (1995) Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression 
blocks the anxiolytic-like action of NPY in amygdala and paradoxically 
increases feeding.  Regul Pept 59: 201-205 
 
Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target 
symptoms and target mechanisms.  Pharmacol Ther 111: 855-876 
 
Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol 
dependence. Trends Neurosci 30: 399-406 
 
Heilig M, Koob GF, Ekman R, Britton KT (1994) Corticotropin-releasing factor and 
neuropeptide Y: role in emotional integration.  Trends Neurosci 17: 80-85 
 
Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT (1993) 
Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in 
amygdala, and dissociation from food intake effects. 
Neuropsychopharmacology 8: 357-363 
 
Heilig M, Soderpalm B, Engel JA, Widerlov E (1989) Centrally administered 
neuropeptide Y (NPY) produces anxiolytic- like effects in animal anxiety 
models. Psychopharmacology 98: 524-529 
 
 97
Heilig M, Widerlov E (1995) Neurobiology and clinical aspects of neuropeptide Y 
Critical Rev Neurobiol, 9: 115-136 
 
Heinrichs SC, Lapsansky J, Lovenberg TW, De Souza EB, Chalmers DT (1997) 
Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate 
anxiogenic-like behavior.  Regul Pept 71: 15-21 
 
Henderson ND, Turri MG, DeFries JC, Flint J (2004) QTL analysis of multiple 
behavioral measures of anxiety in mice. Behav Genet 34: 267-293 
 
Hershon HI (1977) Alcohol withdrawal symptoms and drinking behavior.  J Stud 
Alcohol 38: 953-971 
 
Heyser CJ, Moc K, Koob GF (2003) Effects of naltrexone alone and in combination 
with acamprosate on the alcohol deprivation effect in rats.  
Neuropsychopharmacology 28: 1463-1471 
 
Heyser CJ, Schulteis G, Koob GF (1997) Increased ethanol self-administration after 
a period of imposed ethanol deprivation in rats trained in a limited access 
paradigm. Alcohol Clin Exp Res 21: 784-791 
 
Holly A, Wittchen HU (1998) Patterns of use and their relationship to DSM-IV abuse 
and dependence of alcohol among adolescents and young adults.  Eur Addict 
Res : 50-57 
 
Holter SM, Henniger MS, Lipkowski AW, Spanagel R (2000) Kappa-opioid receptors 
and relapse-like drinking in long-term ethanol-experienced rats. 
Psychopharmacology 153: 93-102 
 
Holter SM, Spanagel R (1999) Effects of opiate antagonist treatment on the alcohol 
deprivation effect in long-term ethanol-experienced rats. 
Psychopharmacology 145: 360-369 
 
Homanics GE, Le NQ, Kist F, Mihalek R, Hart AR, Quinlan JJ (1998) Ethanol 
tolerance and withdrawal responses in GABA(A) receptor alpha 6 subunit null 
allele mice and in inbred C57BL/6J and strain 129/SvJ mice.  Alcohol Clin 
Exp Res 22: 259-265 
 
Hwang BH, Stewart R, Zhang JK, Lumeng L, Li TK (2004) Corticotropin-releasing 
factor gene expression is down-regulated in the central nucleus of the 
amygdala of alcohol-preferring rats which exhibit high anxiety: a comparison 
between rat lines selectively bred for high and low alcohol preference.  Brain 
Res 1026: 143-150 
 
Hwang BH, Zhang JK, Ehlers CL, Lumeng L, Li TK (1999) Innate differences of 
neuropeptide Y (NPY) in hypothalamic nuclei and central nucleus of the 
 98
amygdala between selectively bred rats with high and low alcohol preference.  
Alcohol Clin Exp Res 23: 1023-1030 
 
Johansson B (1992) A review of the pharmacokinetics and pharmacodynamics of 
disulfiram and its metabolites.  Acta Psychiatr Scan Suppl 369: 15-26 
 
Kalra SP, Xu B, Dube MG, Moldawer LL, Martin D, Kalra PS (1998) Leptin and 
ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of 
luteinizing hormone release in rats: role of neuropeptide Y. Neurosci Lett, 
240: 45-49 
 
Kamdar NK, Miller SA, Syed YM, Bhayana R, Gupta T, Rhodes JS (2007) Acute 
effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in 
C57BL/6J mice. Psychopharmacology 192: 207-217 
 
Karlsson RM, Holmes A, Heilig M, Crawley JN (2005) Anxiolytic-like actions of 
centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice.  
Pharmacol Biochem Behav 80: 427-436 
 
Kash TL, Winder DG (2006) Neuropeptide Y and corticotropin-releasing factor bi-
directionally modulate inhibitory synaptic transmission in the bed nucleus of 
the stria terminalis.  Neuropharmacology 51: 1013-1022
 
Kask A, Rägo L, Harro J (1998) Anxiogenic-like effect of the NPY Y1 receptor 
antagonist BIBP3226 administered into the dorsal periaqueductal gray matter 
in rats.  Regul Pept 75-76: 255-262 
 
Kasuya E, Mizuno M, Watanabe G, Terasawa E (1998) Effects of an antisense 
oligodeoxynucleotide for neuropeptide Y mRNA on in vivo luteinizing 
hormone-releasing hormone release in ovariectomized female rhesus 
monkeys. Regul Peptides, 75-76: 319-325 
 
Katner SN, Magalong JG, Weiss F (1999) Reinstatement of alcohol-seeking 
behavior by drug-associated discriminative stimuli after prolonged extinction 
in the rat.  Neuropsychopharmacology 20: 471-479 
 
Keller C, Bruelisauer A, Lemaire M, Enz A (2002) Brain pharmacokinetics of a 
nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab 
Dispos 30: 173-176 
 
King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997) Naltrexone 
biotransformation and incidence of subjective side effects: a preliminary 
study.  Alcohol Clin Exp Res 21:906-909 
 
 99
King PJ, Widdowson PS, Doods H, Williams G (2000) Regulation of neuropeptide Y 
release from hypothalamic slices by melanocortin-4 agonists and leptin.  
Peptides 21: 45-48 
 
Kinoshita H, Jessop DS, Finn DP, Coventry TL, Roberts DJ, Ameno K, Ijiri I, Harbuz 
MS (2000) Acute ethanol decreases NPY mRNA but not POMC mRNA in the 
arcuate nucleus.  Neuroreport 11: 3517-3519  
 
Knapp DJ, Overstreet DH, Breese GR (2007) Baclofen blocks expression and 
sensitization of anxiety-like behavior in an animal model of repeated stress 
and ethanol withdrawal.  Alcohol Clin Exp Res 31: 582-595 
 
Knapp DJ, Overstreet DH, Moy SS, Breese GR (2004) SB242084, flumazenil, and 
CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol 32: 101-
11 
 
Knapp DJ, Saiers JA, Pohorecky LA (1993) Observations of novel behaviors as indices 
of ethanol withdrawal-induced anxiety. In: Taberner PV, Badaway AA (eds) 
Advances in Biomedical Alcohol Research. Pergamon, New York, pp 489-493 
 
Koob GF (2003) Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27: 232-
243 
 
Koob GF (2004) Allostatic view of motivation: implications for psychopathology. Nebr 
Symp Motiv 50: 1-18 
 
Koob GF, Heinrichs SC (1999) A role for corticotropin releasing factor and urocortin 
in behavioral responses to stressors.  Brain Res 848: 141-152 
 
Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, Britton KT 
(1993) The role of corticotropin-releasing factor in behavioural responses to 
stress. Ciba Foundation Symposium 172: 277-289 
 
Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis.  
Neuropsychopharmacology 24: 97-129 
 
Koob GF, Thatcher-Britton K (1985) Stimulant and anxiogenic effects of corticotropin 
releasing factor.  Prog Clin Biol Res 192: 499-506 
  
Kornet M, Goosen C, Ribbens LG, van Ree JM (1990) Analysis of spontaneous 
alcohol drinking in rhesus monkeys. Physiol Behav 47: 679-84 
 
Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M (1998) Obesity 
and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient 
mice.  Proc Natl Acad Sci U S A 95: 15659-15664 
 
 100
Kushner MG, Sher KJ, Wood MD, Wood PK (1994) Anxiety and drinking behavior: 
moderating effects of tension-reduction alcohol outcome expectancies.  
Alcohol Clin Exp Res 18: 852-860 
 
Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000) The role of 
corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking 
behavior in rats. Psychopharmacology 150: 317-24 
 
Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of 
naltrexone and fluoxetine on alcohol self-administration and reinstatement of 
alcohol seeking induced by priming injections of alcohol and exposure to 
stress.  Neuropsychopharmacology 21: 435-444 
 
Le AD, Quan B, Juzytch W, Fletcher PJ, Joharchi N, Shaham Y (1998) 
Reinstatement of alcohol-seeking by priming injections of alcohol and 
exposure to stress in rats.  Psychopharmacology 135: 169-174 
 
Levine AS, Morley JE (1984) Neuropeptide Y: a potent inducer of consummatory 
behavior in rats. Peptides 5: 1025-1029 
 
Li TK, Lumeng L, Doolittle DP (1993) Selective breeding for alcohol preference and 
associated responses.  Behav Genet 23: 163-170 
 
Li Z, Kang SS, Lee S, Rivier C (2005) Effect of ethanol on the regulation of 
corticotropin-releasing factor (CRF) gene expression. Mol Cell Neurosci 29: 
345-354. 
 
Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of 
ethanol seeking: exacerbation by history of dependence and role of 
concurrent activation of corticotropin-releasing factor and opioid mechanisms. 
J Neurosci 22: 7856-61 
 
Lopez MF, Becker HC (2005) Effect of pattern and number of chronic ethanol 
exposures on subsequent voluntary ethanol intake in C57BL/6J mice.  
Psychopharmacology 181: 688-696 
 
Lopez-Valpuesta FJ, Nyce JW, Griffin-Biggs TA, Ice JC, Myers RD (1996) Antisense 
to NPY-Y1 demonstrates that Y1 receptors in the hypothalamus underlie NPY 
hypothermia and feeding in rats. Proc R Soc Lond B Biol Sci 263: 881-886 
 
Ludwig AM (1986) Pavlov's "bells" and alcohol craving.  Addict Behav 11: 87-91 
 
Ludwig AM, Wikler A (1974) "Craving" and relapse to drink.  Q J Stud Alcohol 35: 
108-130 
 
 101
Ludwig AM, Wikler A, Stark LH (1974) The first drink: psychobiological aspects of 
craving.  Arch Gen Psychiatry 30: 539-547 
 
Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, 
Moreau JL (1996) A non peptidic corticotropin releasing factor receptor 
antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J 
Pharmacol 309: 195-200 
 
Mansbach RS, Brooks EN, Chen YL (1997) Antidepressant-like effects of CP-154,526, 
a selective CRF1 receptor antagonist. Eur J Pharmacol 323: 21-26 
 
Martin-Fardon R, Ciccocioppo R, Massi M, Weiss F (2000) Nociceptin prevents 
stress-induced ethanol- but not cocaine-seeking behavior in rats. Neuroreport 
11: 1939-1943 
 
McBride WJ, Le AD, Noronha A (2002)  Central nervous system mechanisms in 
alcohol relapse.  Alcohol Clin Exp Res 26: 280-286. 
 
McBride WJ, Li TK (1998) Animal models of alcoholism: neurobiology of high 
alcohol-drinking behavior in rodents.  Crit Rev Neurobiol 12: 339-369 
 
McCarty CA, Ebel BE, Garrison MH, DiGiuseppe DL, Christakis DA, Rivara FP 
(2004)  Continuity of binge and harmful drinking from late adolesecence to 
early adulthood.  Pediatrics 114:714-719 
 
McKinzie DL, Nowak KL, Yorger L, McBride WJ, Murphy JM, Lumeng L, Li TK 
(1998) The alcohol deprivation effect in the alcohol-preferring P rat under 
free-drinking and operant access conditions. Alcohol Clin Exp Res 22: 1170-
1176 
 
Meijer MK, Spruijt BM, van Zutphen LF, Baumans V (2006) Effect of restraint and 
injection methods on heart rate and body temperature in mice.  Lab Anim 40: 
382-391 
 
Meliska CJ, Bartke A, McGlacken G, Jensen RA (1995) Ethanol, nicotine, 
amphetamine, and aspartame consumption and preferences in C57BL/6 and 
DBA/2 mice.  Pharmacol Biochem Behav 50: 619-626 
 
Mello NK, Mendleson, M.D. (1972) Drinking patterns during work-contingent and 
noncontingent alcohol alcohol acquistion. Psychosom Med 34: 139-164 
 
Merchenthaler I, Vigh S, Petrusz P, Schally AV (1982) Immunocytochemical 
localization of corticotropin-releasing factor (CRF) in the rat brain. Am J Anat 
165: 385-396 
 
 102
Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, 
Weiss F (1995) Increase of extracellular corticotropin-releasing factor-like 
immunoreactivity levels in the amygdala of awake rats during restraint stress 
and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439-
47 
 
Middaugh LD, Kelley BM, Bandy AL, McGroarty KK (1999) Ethanol consumption by 
C57BL/6 mice: influence of gender and procedural variables.  Alcohol 17: 
175-183 
 
Middaugh LD, Lee AM, Bandy AL (2000a) Ethanol reinforcement in nondeprived 
mice: effects of abstinence and naltrexone. Alcohol Clin Exp Res 24: 1172-9 
 
Middaugh LD, Szumlinski KK, Van Patten Y, Marlowe A-LB, Kalivas PW (2000b) 
Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its 
interoceptive cues and increases extracellular dopamine, an effect blocked by 
naltrexone. Alcohol Clin Exp Res 27: 1892-1900 
 
Miller WR, Harris RJ (2000) A simple scale of Gorski's warning signs for relapse.  J 
Stud Alcohol 61: 759-765 
 
Mokdad AH, Brewer RD, Naimi T, Warner L (2007) Binge drinking is a problem that 
cannot be ignored.  Prev Med 44: 303-304 
 
Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, 
Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone's effect on cue-elicited 
craving among alcoholics in treatment.  Alcohol Clin Exp Res 23: 1386-1394 
 
Mossberg D, Liljeberg P, Borg S (1985) Clinical conditions in alcoholics during long-
term abstinence: a descriptive, longitudinal treatment study.  Alcohol 2: 551-
553 
 
Moy SS, Knapp DJ, Criswell HE, Breese GR (1997) Flumazenil blockade of anxiety 
following ethanol withdrawal in rats.  Psychopharmacology 131: 354-360 
 
Moy SS, Knapp DJ, Duncan GE, Breese GR (2000) Enhanced ultrasonic 
vocalization and Fos protein expression following ethanol withdrawal: effects 
of flumazenil.  Psychopharmacology 152: 208-215 
 
Murphy JM, Gatto GJ, Waller MB, McBride WJ, Lumeng L, Li TK (1986) Effects of 
scheduled access on ethanol intake by the alcohol-preferring (P) line of rats.  
Alcohol 3: 331-336 
 
Murphy JM, Stewart RB, Bell RL, Badia-Elder NE, Carr LG, McBride WJ, Lumeng L, 
Li TK (2002) Phenotypic and genotypic characterization of the Indiana 
 103
University rat lines selectively bred for high and low alcohol preference.  
Behav Genet 32: 363-388. 
 
Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E (2003) Acamprosate in Korean 
alcohol-dependent patients: a multi-centre, randomized, double-blind, 
placebo-controlled study.  Alcohol 38: 135-141 
 
Navarro M, Cubero I, Knapp DJ, Thiele TE (2003) MTII-induced reduction of voluntary 
ethanol drinking is blocked by pretreatment with AgRP-(83-132). Neuropeptides 
37: 338-344 
 
Nie H, Janak PH (2003) Comparison of reinstatement of ethanol- and sucrose-
seeking by conditioned stimuli and priming injections of allopregnanolone 
after extinction in rats.  Psychopharmacology 168: 222-228 
 
O'Brien CP, Childress AR, Ehrman R, Robbins SJ (1998) Conditioning factors in 
drug abuse: can they explain compulsion? J Psychopharmacol 12: 15-22 
 
O'Dell LE, Roberts AJ, Smith RT, Koob GF (2004) Enhanced alcohol self-
administration after intermittent versus continuous alcohol vapor exposure.  
Alcohol Clin Exp Res 28: 1676-1682 
 
Olive MF, Koenig HN, Nannini MA, Hodge CW (2002) Elevated extracellular CRF 
levels in the bed nucleus of the stria terminalis during ethanol withdrawal and 
reduction by subsequent ethanol intake. Pharmacol Biochem Behav 72: 213-
220 
 
O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) 
Naltrexone and coping skills therapy for alcohol dependence. A controlled 
study.  Arch Gen Psychiatry 49: 881-887 
 
Overstreet DH, Knapp DJ, Angel RA, Navarro M, Breese GR (2006) Reduction in 
repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective 
injections of 5-HT(1A) and 5-HT (2C) ligands.  Psychopharmacology 187: 1-
12 
 
Overstreet DH, Knapp DJ, Breese GR (2002) Accentuated decrease in social 
interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp 
Res 26: 1259-68 
 
Overstreet DH, Knapp DJ, Breese GR (2004) Modulation of multiple ethanol 
withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. 
Pharmacol Biochem Behav 77: 405-13 
 
Palmiter RD, Erickson, JC, Hollopeter, G, Baraban, SC, Schwartz, MW (1998) Life 
without neuropeptide Y, Recent Prog Horm Res, 53: 163-199 
 104
 
Pandey SC (2003) Anxiety and alcohol abuse disorders: a common role for CREB 
and its target, the neuropeptide Y gene. Trends Pharmacol Sci 24: 456-60 
 
Pandey SC, Carr LG, Heilig M, Ilveskoski E, Thiele TE (2003a) Neuropeptide Y and 
alcoholism: genetic, molecular, and pharmacological evidence. Alcohol Clin 
Exp Res 27: 149-154 
 
Pandey SC, Roy A, Mittal N (2001) Effects of chronic ethanol intake and its 
withdrawal on the expression and phosphorylation of the creb gene 
transcription factor in rat cortex. J Pharmacol Exp Ther 296: 857-868 
 
Pandey SC, Roy A, Zhang H (2003b) The decreased phosphorylation of cyclic 
adenosine monophosphate (cAMP) response element binding (CREB) protein 
in the central amygdala acts as a molecular substrate for anxiety related to 
ethanol withdrawal in rats. Alcohol Clin Exp Res 27: 396-409 
 
Pandey SC, Zhang H, Roy A, Xu T (2005) Deficits in amygdaloid cAMP-responsive 
element-binding protein signaling play a role in genetic predisposition to 
anxiety and alcoholism.  J Clin Invest 115: 2762-2773 
 
Parsons OA, Schaeffer KW, Glenn SW (1990) Does neuropsychological test 
performance predict resumption of drinking in posttreatment alcoholics?  
Addict Behav 15: 297-307 
 
Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F,  
Brunner HR (1998) Cardiovascular response, feeding behavior and locomotor 
activity in mice lacking the NPY Y1 receptor. Nat Med 4: 722-726 
 
Perrin M, Donaldson C, Chen R, Blount A, Berggren T, Bilezikjian L, Sawchenko P, 
Vale W (1995) Identification of a second corticotropin-releasing factor 
receptor gene and characterization of a cDNA expressed in heart.  Proc Natl 
Acad Sci U S A 92: 2969-2973 
 
Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW (2000) 
Chronic daily ethanol and withdrawal: 1. Long-term changes in the 
hypothalamo-pituitary-adrenal axis. Alcohol Clin Exp Res 24: 1836-49 
 
Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a 
corticotropin-releasing factor antagonist into the central nucleus of the 
amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 
605: 25-32 
 
Reul JM, Holsboer F (2002) Corticotropin-releasing factor receptors 1 and 2 in 
anxiety and depression.  Curr Opin Pharmacol 2: 23-33 
 
 105
Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC (2005) Evaluation of a simple 
model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 84: 
53-63 
 
Rhodes JS, Ford MM, Yu CH, Brown LL, Finn DA, Garland T, Jr., Crabbe JC (2007) 
Mouse inbred strain differences in ethanol drinking to intoxication. Genes Brain 
Behav 6: 1-18 
 
Rhodes ME, Billings TE, Czambel RK, Rubin RT (2005b) Pituitary-adrenal 
responses to cholinergic stimulation and acute mild stress are differentially 
elevated in male and female M(2) muscarinic receptor knockout mice.  J 
Neuroendocrinol 17: 817-826 
 
Richter RM, Weiss F (1999) In vivo CRF release in rat amygdala is increased during 
cocaine withdrawal in self-administering rats.  Synapse 32: 254-261 
 
Rimondini R, Arlinde C, Sommer W, Heilig M (2002) Long-lasting increase in 
voluntary ethanol consumption and transcriptional regulation in the rat brain 
after intermittent exposure to alcohol.  FASEB J 16: 27-35  
 
Rimondini R, Sommer W, Heilig M (2003) A temporal threshold for induction of 
persistent alcohol preference: behavioral evidence in a rat model of 
intermittent intoxication.  J Stud Alcohol 64: 445-449 
 
Rimondini R, Thorsell A, Heilig M (2005) Suppression of ethanol self-administration 
by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for 
sensitization in rats with a history of dependence.  Neurosci Lett 375: 129-133 
 
Rivier C (1996) Alcohol stimulates ACTH secretion in the rat: mechanisms of action 
and interactions with other stimuli. Alcohol Clin Exp Res 20: 240-254 
 
Rivier C, Bruhn T, Vale W (1984) Effect of ethanol on the hypothalamic-pituitary-
adrenal axis in the rat: role of corticotropin-releasing factor (CRF). J 
Pharmacol Exp Ther 229: 127-31 
 
Rivier C, Imaki T, Vale W (1990) Prolonged exposure to alcohol: effect on CRF mRNA 
levels, and CRF- and stress-induced ACTH secretion in the rat. Brain Res 520: 
1-5 
 
Rivier C, Lee S (1996) Acute alcohol administration stimulates the activity of 
hypothalamic neurons that express corticotropin-releasing factor and 
vasopressin. Brain Res 726: 1-10 
 
Roberts AJ, Cole M, Koob GF (1996) Intra-amygdala muscimol decreases operant 
ethanol self-administration in dependent rats.  Alcohol Clin Exp Res 20: 1289-
1298 
 106
 
Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF (2000) Excessive ethanol 
drinking following a history of dependence: animal model of allostasis.  
Neuropsychopharmacology 22: 581-594 
 
Rodd ZA, Bell RL, Kuc KA, Murphy JM, Lumeng L, Li TK, McBride WJ (2003) Effects 
of repeated alcohol deprivations on operant ethanol self-administration by 
alcohol-preferring (P) rats. Neuropsychopharmacology 28: 1614-21 
 
Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride 
WJ (2006) The metabotropic glutamate 2/3 receptor agonist LY404039 
reduces alcohol-seeking but not alcohol self-administration in alcohol-
preferring (P) rats.  Behav Brain Res 171: 207-215 
 
Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK 
(2001) Effects of concurrent access to multiple ethanol concentrations and 
repeated deprivations on alcohol intake of alcohol-preferring rats. Alcohol Clin 
Exp Res 25: 1140-50 
 
Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK 
(2002a) Effects of ethanol exposure on subsequent acquisition and extinction 
of ethanol self-administration and expression of alcohol-seeking behavior in 
adult alcohol-preferring (P) rats: I. Periadolescent exposure. Alcohol Clin Exp 
Res 26: 1632-41 
 
Rodd-Henricks ZA, Bell RL, Kuc KA, Murphy JM, McBride WJ, Lumeng L, Li TK 
(2002b) Effects of ethanol exposure on subsequent acquisition and extinction 
of ethanol self-administration and expression of alcohol-seeking behavior in 
adult alcohol-preferring (P) rats: II. Adult exposure. Alcohol Clin Exp Res 26: 
1642-52 
 
Rodd-Henricks ZA, McKinzie DL, Edmundson VE, Dagon CL, Murphy JM, McBride 
WJ, Lumeng L, Li TK (2000) Effects of 5-HT(3) receptor antagonists on daily 
alcohol intake under acquisition, maintenance, and relapse conditions in 
alcohol-preferring (P) rats.  Alcohol 21: 73-85 
 
Rogers J, Wiener SG, Bloom FE (1979) Long-term ethanol administration methods 
for rats: advantages of inhalation over intubation or liquid diets.  Behav Neuro 
Biol 27: 466-486 
 
Roy A, Pandey SC (2002) The decreased cellular expression of neuropeptide Y 
protein in rat brain structures during ethanol withdrawal after chronic ethanol 
exposure. Alcohol Clin Exp Res 26: 796-803 
 
 107
Sabino V, Cottone P, Koob GF, Steardo L, Lee MJ, Rice KC, Zorrilla EP (2006) 
Dissociation between opioid and CRF1 antagonist sensitive drinking in 
Sardinian alcohol-preferring rats. Psychopharmacology 189: 175-186 
 
Sajdyk TJ, Vandergriff MG, Gehlert DR (1999) Amygdalar neuropeptide Y Y1 
receptors mediate the anxiolytic-like actions of neuropeptide Y in the social 
interaction test.  Eur J Pharmacol 368: 143-147 
 
Salimov R, Salimova N, Klodt P, Maisky A (1993) Interaction between alcohol 
deprivation and morphine withdrawal in mice.  Drug Alcohol Depend 34: 59-
66  
 
Salimov RM, Salimova NB (1993a) L-glutamate abolishes differential responses to 
alcohol deprivation in mice.  Alcohol 10: 251-257 
 
Salimov RM, Salimova NB (1993b) The alcohol-deprivation effect in hybrid mice.  
Drug Alcohol Depend 32: 187-191 
 
Samson HH (1986) Initiation of ethanol reinforcement using a sucrose-substitution 
procedure in food- and water-sated rats. Alcohol Clin Exp Res 10: 436-442 
 
Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Bachteler D, Gass P,  
Sprengel R, Spanagel R (2006) Involvement of the AMPA receptor GluR-C 
subunit in alcohol-seeking behavior and relapse. J Neurosci 26: 1231-8 
 
Schroeder JP, Iller KA, Hodge CW (2003b) Neuropeptide-Y Y5 receptors modulate 
the onset and maintenance of operant ethanol self-administration. Alcohol 
Clin Exp Res 27: 1912-1920 
 
Schroeder JP, Olive F, Koenig H, Hodge CW (2003a) Intra-amygdala infusion of the 
NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-
administration.  Alcohol Clin Exp Res 27: 1884-1891 
 
Schuckit MA, Hesselbrock V (1994) Alcohol dependence and anxiety disorders: 
what is the relationship? Am J Psychiatry 151: 1723-1734 
 
Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, 
Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD, 3rd, 
Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective 
nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl 
Acad Sci U S A 93: 10477-82 
 
Shaham Y, Erb S, Stewart J (2000) Stress-induced relapse to heroin and cocaine 
seeking in rats: a review.  Brain Res Brain Res Rev 33: 1333 
 
 108
Shi TJ, Cui JG, Meyerson BA, Linderoth B, Hokfelt T (1999) Regulation of galanin 
and neuropeptide Y in dorsal root ganglia and dorsal horn in rat 
mononeuropathic models: possible relation to tactile hypersensitivity. 
Neuroscience 93: 741-757 
 
Shi TJ, Tandrup T, Bergman E, Xu ZQ, Ulfhake B, Hokfelt T (2001) Effect of 
peripheral nerve injury on dorsal root ganglion neurons in the C57 BL/6J 
mouse: marked changes both in cell numbers and neuropeptide expression. 
Neuroscience 105: 249-263 
 
Sinclair JD (1971) The alcohol-deprivation effect in monkeys. Psychon Sci 25: 1-22 
 
Sinclair JD, Li TK (1989) Long and short alcohol deprivation: effects on AA and P 
alcohol-preferring rats.  Alcohol 6: 505-509 
 
Sinclair JD, Senter RJ (1968) Development of an alcohol-deprivation effect in rats.  
Q J Stud Alcohol 29: 863-867 
 
Sinclair JD, Walker S, Jordan W (1973) Behavioral and physiological changes 
associated with various durations of alcohol deprivation in rats.  Q J Stud 
Alcohol 34: 744-757 
 
Sinha R (2001) How does stress increase risk of drug abuse and relapse? 
Psychopharmacology 158: 343-359 
 
Smith-White MA, Hardy TA, Brock JA, Potter EK (2001) Effects of a selective 
neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at 
peripheral neuroeffector junctions.  Br J Pharmacol 132: 861-868 
 
Spanagel R (2000) Recent animal models of alcoholism. Alcohol Res Health 24: 124-
131 
 
Spanagel R, Bienkowski P (2002) Glutamatergic mechanisms in alcohol 
dependence and addiction In: Lodge D, Danysz W, Parsons CG (eds) 
Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and 
Modulators. Graham Publishing Co.: Johnson City, TN, pp. 375-403 
 
Spanagel R, Holter SM (1999) Long-term alcohol self-administration with repeated 
alcohol deprivation phases: an animal model of alcoholism? Alcohol 34: 231-
243 
 
Spanagel R, Holter SM, Allingham K, Landgraf R, Zieglgansberger W (1996) 
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol 
deprivation in the rat. Eur J Pharmacol 305: 39-44 
 
 109
Spanagel R, Zieglgänsberger W (1997) Anti-craving compounds for ethanol: new 
pharmacological tools to study addictive processes. Trends Pharmacol Sci 
18: 54-59 
 
Sparta DR, Fee JR, Hayes DM, Knapp DJ, MacNeil DJ, Thiele TE (2004) Peripheral 
and central administration of a selective neuropeptide Y Y1 receptor 
antagonist suppresses ethanol intake by C57BL/6J mice.  Alcohol Clin Exp 
Res 28: 1324-1330 
 
Sparta DR, Fee JR, Knapp DJ, Breese GR, Thiele TE (2007) Elevated anxiety-like 
behavior following ethanol exposure in mutant mice lacking neuropeptide Y 
(NPY).  Drug Alcohol Depend 90: 297-300 
 
Stahre M, Naimi T, Brewer R, Holt J (2006) Measuring average alcohol 
consumption: the impact of including binge drinks in quantity-frequency 
calculations.  Addiction 101: 1711-1718 
Staiger PK, White JM (1988) Conditioned alcohol-like and alcohol-opposite 
responses in humans.  Psychopharmacology 95: 87-91 
 
Stewart J (2000) Pathways to relapse: the neurobiology of drug- and stress-induced 
relapse to drug-taking.  J Psychiatry Neurosci 25: 125-136 
 
Stewart J (2004) Pathways to relapse: factors controlling the reinitiation of drug 
seeking after abstinence. Nebr Symp Motiv 50: 197-234 
 
Stewart RB, Gatto GJ, Lumeng L, Li TK, Murphy JM (1993) Comparison of alcohol-
preferring (P) and nonpreferring (NP) rats on tests of anxiety and for the 
anxiolytic effects of ethanol.  Alcohol 10: 1-10 
 
Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME, Himms-Hagen 
J, Flier JS, Lowell BB (1995) Targeted disruption of the beta 3-adrenergic 
receptor gene.  J Biol Chem 270: 29483-29492 
 
Swanson LW, Sawchenko PE, Rivier J, Vale WW (1983) Organization of ovine 
corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: 
an immunohistochemical study. Neuroendocrinology 36: 165-186 
 
Tapert SF, Brown GG, Baratta MV, Brown SA (2004) fMRI BOLD response to 
alcohol stimuli in alcohol dependent young women.  Addict Behav 29:33-50 
 
Thiele TE, Knapp DJ, Overstreet DH, Navarro M, Breese GR, McCown TJ (2007) 
Amygdalar transduction by a rAAV vector causing constitutive secretion of 
NPY blocks the alcohol deprivation effect and anxiety-like behavior in Alcohol 
Preferring P rats.  Society for Neuroscience abstract   
 
 110
Thiele TE, Koh MT, Pedrazzini T (2002) Voluntary alcohol consumption is controlled 
via the neuropeptide Y Y1 receptor. J Neurosci 22: RC208 
 
Thiele TE, Marsh DJ, Ste. Marie L, Bernstein IL, Palmiter RD (1998) Ethanol 
consumption and resistance are inversely related to neuropeptide Y levels. 
Nature 396: 366-9 
 
Thiele TE, Miura GI, Marsh DJ, Bernstein IL, Palmiter RD (2000) Neurobiological 
responses to ethanol in mutant mice lacking neuropeptide Y or the Y5 
receptor. Pharmacol Biochem Behav 67: 683-691 
 
Thiele TE, Naveilhan P, Ernfors P (2004) Assessment of ethanol consumption and 
water drinking by NPY Y(2) receptor knockout mice. Peptides 25: 975-983 
 
Thiele TE, Sparta DR, Fee JR, Navarro M, Cubero I (2003) Central neuropeptide Y 
alters ethanol-induced sedation, but not ethanol intake, in C57BL/6 mice. 
Alcohol 31: 155-160 
 
Thiele TE, Sparta DR, Hayes DM, Fee JR (2004) A role for neuropeptide Y in 
neurobiological responses to ethanol and drugs of abuse. Neuropeptides 
38(4): 235-43 
 
Thorsell A, Repunte-Canonigo V, O'Dell LE, Chen SA, King AR, Lekic D, Koob GF, 
Sanna PP (2007) Viral vector-induced amygdala NPY overexpression 
reverses increased alcohol intake caused by repeated deprivations in Wistar 
rats.  Brain 130: 1330-1337 
 
Thorsell A, Rimondini R, Heilig M (2002) Blockade of central neuropeptide Y (NPY) 
Y2 receptors reduces ethanol self-administration in rats. Neurosci Lett, 332: 
1-4 
 
Thorsell A, Slawecki CJ, Ehlers CL (2005a) Effects of neuropeptide Y and 
corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with 
chronic ethanol exposure.  Behav Brain Res 161: 133-140 
 
Thorsell A, Slawecki CJ, Ehlers CL (2005b) Effects of neuropeptide Y on appetitive 
and consummatory behaviors associated with alcohol drinking in wistar rats 
with a history of ethanol exposure.  Alcohol Clin Exp Res 29: 584-590 
 
Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler 
T, T Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety 
in mice lacking a functional corticotropin-releasing hormone receptor 1.  Nat 
Genet 19: 162-166 
 
 111
Turri MG, Datta SR, DeFries J, Henderson ND, Flint J (2001) QTL analysis identifies 
multiple behavioral dimensions in ethological tests of anxiety in laboratory 
mice. Curr Biol 11: 725-34 
 
Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M, Saam C, Lascorz J, 
Soyka M, Preuss UW, Rujescu D, Skowronek MH, Rietschel M, Spanagel R, 
Heinz A, Laucht M, Mann K, Schumann G (2006) Genetic association of the 
human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking 
and alcohol intake patterns in two independent samples. Mol Psychiatry 11: 
594-602 
 
Tsai G, Coyle JT (1998). The role of glutamatergic neurotransmission in the 
pathophysiology of alcoholism. Annu Rev Med 49: 173-184
 
Valdez GR (2006) Development of CRF1 receptor antagonists as antidepressants and 
anxiolytics: progress to date. CNS Drugs 20: 887-896 
 
Valdez GR, Koob GF (2004) Allostasis and dysregulation of corticotropin-releasing 
factor and neuropeptide Y systems: implications for the development of 
alcoholism.  Pharmacol Biochem Behav 79: 671-689 
 
Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP, Koob GF (2002) 
Increased ethanol self-administration and anxiety-like behavior during acute 
ethanol withdrawal and protracted abstinence: regulation by corticotropin-
releasing factor. Alcohol Clin Exp Res 26: 1494-1501 
 
Valdez GR, Sabino V, Koob GF (2004) Increased anxiety-like behavior and ethanol 
self-administration in dependent rats: reversal via corticotropin-releasing 
factor-2 receptor activation.  Alcohol Clin Exp Res 28: 865-872 
 
Vengeliene V, Bachteler D, Danysz W, Spanagel R (2005) The role of the NMDA 
receptor in alcohol relapse: a pharmacological mapping study using the 
alcohol deprivation effect. Neuropharmacology 48: 822-829 
 
Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) 
Naltrexone and alcohol dependence. Role of subject compliance.  Arch Gen 
Psychiatry 54: 691-694 
 
Wahlsten D, Metten P, Phillips TJ, Boehm SL, 2nd, Burkhart-Kasch S, Dorow J, 
Doerksen S, Downing C, Fogarty J, Rodd-Henricks K, Hen R, McKinnon CS, 
Merrill CM, Nolte C, Schalomon M, Schlumbohm JP, Sibert JR, Wenger CD, 
Dudek BC, Crabbe JC (2003) Different data from different labs: lessons from 
studies of gene-environment interaction. J Neurobiol 54: 283-311 
 
 112
Waller MB, McBride WJ, Lumeng L, Li TK (1982) Effects of intravenous ethanol and 
of 4-methylpyrazole on alcohol drinking in alcohol-preferring rats. Pharmacol 
Biochem Behav 17: 763-768 
 
Wang L, Martínez V, Rivier JE, Taché Y (2001) Peripheral urocortin inhibits gastric 
emptying and food intake in mice: differential role of CRF receptor 2.  Am J 
Physiol Regul Integr Comp Physiol 281: R1401-1410 
 
Winer BJ, Brown DR, Michels KM (1991) Statistical Principles in Experimental 
Design, Third edn. McGraw-Hill, Inc., McGraw-Hill, Inc. 
 
Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, Bolwig TG (1997) 
Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like 
receptors. Nat Med 3: 761-764 
 
Woldbye DP, Madsen TM, Larsen PJ, Mikkelsen JD, Bolwig TG (1996) 
Neuropeptide Y inhibits hippocampal seizures and wet dog shakes. Brain Res 
737: 162-168 
 
Woldbye DP, Ulrichsen J, Haugbøl S, Bolwig TG (2002) Ethanol withdrawal in rats is 
attenuated by intracerebroventricular administration of neuropeptide Y.  
Alcohol 37: 318-321 
 
Wolffgramm J, Heyne A (1995) From controlled drug intake to loss of control: the 
irreversible development of drug addiction in the rat. Behav Brain Res 70: 77-
94 
 
Xu JF, Chen XQ, Du JZ, Wang TY (2005) CRF receptor type 1 mediates continual  
hypoxia-induced CRF peptide and CRF mRNA expression increase in  
hypothalamic PVN of rats. Peptides 26: 639-646 
 
Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) 
Effects of the high-affinity corticotropin-releasing hormone receptor 1 
antagonist R121919 in major depression: the first 20 patients treated.  J 
Psychiatr Res 34: 171-181 
 
Zorrilla EP, Valdez GR, Weiss F (2001) Changes in levels of regional CRF-like- 
immunoreactivity and plasma corticosterone during protracted drug  
withdrawal in dependent rats. Psychopharmacology 158: 374-381 
 
 
 
 
 113
